[
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸ç³»çµ±å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»æ–¹å¼çš„è®ŠåŒ–ï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è¶Šä¾†è¶Šå—åˆ°é‡è¦–ï¼Œå› æ­¤é€™äº›å¤©ç„¶æˆåˆ†çš„ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºç›¸é—œç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘èƒå–ä¾†ç²å¾—çš„ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒå¤§å°çš„GO-PEGå¥ˆç±³ç²’å­ï¼Œä¸¦ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡å’ŒIC50å€¼ï¼Œé€™æ¨£å¯ä»¥äº†è§£é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ç¨‹åº¦ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå®ƒå€‘çš„å…·é«”ç™‚æ•ˆå’Œæ‡‰ç”¨æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸ç³»çµ±å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚éš¨è‘—ç’°å¢ƒæ±¡æŸ“å’Œç”Ÿæ´»æ–¹å¼çš„è®ŠåŒ–ï¼Œå‘¼å¸ç³»çµ±çš„å¥åº·è¶Šä¾†è¶Šå—åˆ°é‡è¦–ï¼Œå› æ­¤é€™äº›å¤©ç„¶æˆåˆ†çš„ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºç›¸é—œç–¾ç—…çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯é€šéèª¿æ•´pHå€¼çš„æ°´è™•ç†å’Œæœ‰æ©Ÿæº¶åŠ‘èƒå–ä¾†ç²å¾—çš„ï¼Œä¸¦ä½¿ç”¨é«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒå¤§å°çš„GO-PEGå¥ˆç±³ç²’å­ï¼Œä¸¦ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡å’ŒIC50å€¼ï¼Œé€™æ¨£å¯ä»¥äº†è§£é€™äº›ç‰©è³ªå°ç´°èƒçš„å½±éŸ¿ç¨‹åº¦ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå®ƒå€‘çš„å…·é«”ç™‚æ•ˆå’Œæ‡‰ç”¨æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±æœ‰é©šäººçš„å¥½è™•ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·æˆ‘å€‘çš„å‘¼å¸é“ç´°èƒï¼Œé€™å°æ–¼æ”¹å–„å‘¼å¸å¥åº·éå¸¸é‡è¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†å¹¾ç¨®å¤©ç„¶æˆåˆ†ï¼ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œçœ‹çœ‹å®ƒå€‘å°å‘¼å¸é“ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸€ç¨®ç‰¹æ®Šçš„ç´°èƒä¾†é€²è¡Œå¯¦é©—ï¼Œä¸¦æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„é€™äº›æˆåˆ†ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ä¸€ç¨®åç‚ºIL-6çš„ç™¼ç‚ç‰©è³ªï¼Œä¸¦æå‡æˆ‘å€‘é«”å…§çš„æŠ—æ°§åŒ–é…¶æ´»æ€§ï¼Œé€™äº›é…¶æœ‰åŠ©æ–¼æŠµæŠ—æ°§åŒ–å£“åŠ›ã€‚\n\né›–ç„¶é€™äº›çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªé€™äº›å¤©ç„¶æˆåˆ†çš„å…·é«”ç™‚æ•ˆã€‚ä»¥ä¸‹æ˜¯é€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š\n- è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸ç³»çµ±æœ‰ä¿è­·ä½œç”¨ã€‚\n- é€™äº›æˆåˆ†èƒ½é™ä½ç™¼ç‚ç‰©è³ªçš„æ°´å¹³ã€‚\n- æœ‰åŠ©æ–¼æå‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œå°å¥åº·æœ‰æ½›åœ¨å¹«åŠ©ï¼",
    "image_prompt": "Create an informative and simplified illustration explaining the experiment and main results of a study on the health benefits of daikon sulforaphane and black radish juice. The image should have a flat design style with a white or light-colored background and soft color palette. Include symbols representing daikon or sulforaphane, simplified representations of human or cell subjects, arrows or flow lines indicating the experimental steps, and a section clearly labeling the 'Main Results' such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸ç³»çµ±ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·æˆ–ç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç ”ç©¶é¡¯ç¤ºï¼Œå¤©ç„¶ç”¢å“å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„åˆæˆæ··åˆç‰©å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤æ´»æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†å¯èƒ½æœƒæœ‰æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æé«˜å…¶æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€šéåˆæˆæ–°çš„åŒ–åˆç‰©ä¾†å¢å¼·å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦æ¢ç´¢é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¾è€Œç‚ºæ²»ç™‚é€™ç¨®é›£æ²»æ€§ç™Œç—‡æä¾›æ–°çš„å¯èƒ½æ€§ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™Œæ•ˆæœé€²è¡Œè©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©åœ¨é«”å¤–çš„æ¸¬è©¦ä¸­ï¼Œä¸»è¦é‡å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒé€²è¡Œï¼Œè§€å¯Ÿå…¶å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œå°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„IC50å€¼ç¯„åœç‚º0.85è‡³1.34å¾®æ‘©çˆ¾ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ‘åˆ¶æ•ˆæœã€‚17aä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯æ¯’æ€§ï¼Œé€™äº›çµæœé¡¯ç¤º17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ–°å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·æˆ–ç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç ”ç©¶é¡¯ç¤ºï¼Œå¤©ç„¶ç”¢å“å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„åˆæˆæ··åˆç‰©å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤æ´»æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†å¯èƒ½æœƒæœ‰æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æé«˜å…¶æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€šéåˆæˆæ–°çš„åŒ–åˆç‰©ä¾†å¢å¼·å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„æŠ‘åˆ¶ä½œç”¨ï¼Œä¸¦æ¢ç´¢é€™äº›åŒ–åˆç‰©çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¾è€Œç‚ºæ²»ç™‚é€™ç¨®é›£æ²»æ€§ç™Œç—‡æä¾›æ–°çš„å¯èƒ½æ€§ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—ç™Œæ•ˆæœé€²è¡Œè©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©åœ¨é«”å¤–çš„æ¸¬è©¦ä¸­ï¼Œä¸»è¦é‡å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒé€²è¡Œï¼Œè§€å¯Ÿå…¶å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è©•ä¼°é€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œå°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„IC50å€¼ç¯„åœç‚º0.85è‡³1.34å¾®æ‘©çˆ¾ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ‘åˆ¶æ•ˆæœã€‚17aä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯æ¯’æ€§ï¼Œé€™äº›çµæœé¡¯ç¤º17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ–°å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½æˆç‚ºç™Œç—‡æ²»ç™‚çš„æ–°å¸Œæœ›ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®ç‰¹åˆ¥é›£å°ä»˜çš„ç™Œç—‡ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç§‘å­¸å®¶å€‘ç™¼ç¾ï¼Œåƒè˜¿è””ç¡«ç´ é€™æ¨£çš„å¤©ç„¶ç”¢å“å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚\n\né€™é …ç ”ç©¶çš„ç›®çš„æ˜¯é–‹ç™¼ä¸€ç³»åˆ—æ–°çš„åŒ–åˆç‰©ï¼Œçµåˆæœ¨è˜­é…šå’Œè˜¿è””ç¡«ç´ ï¼Œä»¥å¢å¼·å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…å€‘è¨­è¨ˆäº†15ç¨®ä¸åŒçš„æ··åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤ä¸­è§€å¯Ÿå®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡ã€‚\n\nçµæœé¡¯ç¤ºï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé‚„èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚æ›´é©šäººçš„æ˜¯ï¼Œé€™ç¨®åŒ–åˆç‰©åœ¨å°é¼ æ¨¡å‹ä¸­ä¹Ÿèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©å¯èƒ½ç‚ºä¸‰é™°æ€§ä¹³ç™Œæä¾›æ–°çš„æ²»ç™‚é¸æ“‡ã€‚\n2. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºé¡¯è‘—çš„æŠ—è…«ç˜¤æ•ˆæœã€‚\n3. é€™äº›ç ”ç©¶çµæœç‚ºæœªä¾†çš„è‡¨åºŠç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a simple and informative infographic that explains the experimental methods and main results of a study on natural compounds for cancer treatment. Use a flat design style with a light background and soft colors. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, or cells), arrows or flow lines to represent experimental steps, and a section that highlights the main results, such as protective effects and observed changes.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰é›–ç„¶æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚é€™æ„å‘³è‘—æˆ‘å€‘éœ€è¦æ›´æ·±å…¥åœ°äº†è§£é€™ç¨®ç–¾ç—…çš„æ©Ÿåˆ¶ï¼Œä¸¦å°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡åœ¨TTSçš„ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œå› æ­¤é‡å°é€™äº›å› ç´ çš„æ²»ç™‚å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³ã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œå¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å¯èƒ½åœ¨ç–¾ç—…é é˜²å’Œæ²»ç™‚ä¸­ç™¼æ®æ½›åœ¨çš„ä½œç”¨ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶å’Œæ¢ç´¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®ç—‡å€™ç¾¤çš„ç—…ç†æ©Ÿåˆ¶ï¼Œä»¥åŠå¦‚ä½•é€šéç‰¹å®šçš„æ²»ç™‚ä¾†æ¸›è¼•å…¶é€ æˆçš„å¿ƒè‚Œæå‚·ã€‚ç”±æ–¼ç›®å‰å°šç„¡é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡é¡¯å¾—å°¤ç‚ºé‡è¦ã€‚ç ”ç©¶ä¸­ï¼Œè˜¿è””ç¡«ç´ è¢«è¦–ç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ¿€æ´»åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„TTSç›¸é—œçš„å¿ƒè‚Œæå‚·ï¼Œé€™å¼•èµ·äº†ç ”ç©¶è€…çš„èˆˆè¶£ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬Takotsuboç—‡å€™ç¾¤ã€‚ç ”ç©¶çš„ä¸»è¦æ–¹æ³•æ˜¯è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¿ƒè‚Œçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·æƒ…æ³ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ï¼Œä¸¦æ¯”è¼ƒäº†è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚Fer-1ï¼‰çš„æ•ˆæœï¼Œä»¥äº†è§£å…¶ç¨ç‰¹çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼Œä¸¦æŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚èˆ‡Fer-1ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ ç¨ç‰¹åœ°æ¿€æ´»äº†Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºå…¶é›™é‡ä½œç”¨çš„æ½›åŠ›ã€‚ç„¶è€Œï¼Œç•¶Nrf2è¢«æŠ‘åˆ¶æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœæœƒæ¶ˆå¤±ï¼Œé€™å¼·èª¿äº†Nrf2åœ¨å…¶æ²»ç™‚æ•ˆæœä¸­çš„é—œéµè§’è‰²ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ”¹å–„Takotsuboç—‡å€™ç¾¤çµæœçš„æ½›åœ¨æ²»ç™‚é¸æ“‡ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰é›–ç„¶æ›¾è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‚Œæå‚·ã€‚é€™æ„å‘³è‘—æˆ‘å€‘éœ€è¦æ›´æ·±å…¥åœ°äº†è§£é€™ç¨®ç–¾ç—…çš„æ©Ÿåˆ¶ï¼Œä¸¦å°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œæ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡åœ¨TTSçš„ç™¼å±•ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œå› æ­¤é‡å°é€™äº›å› ç´ çš„æ²»ç™‚å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³ã€‚é€™ä¹Ÿæé†’æˆ‘å€‘ï¼Œå¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å¯èƒ½åœ¨ç–¾ç—…é é˜²å’Œæ²»ç™‚ä¸­ç™¼æ®æ½›åœ¨çš„ä½œç”¨ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶å’Œæ¢ç´¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®ç—‡å€™ç¾¤çš„ç—…ç†æ©Ÿåˆ¶ï¼Œä»¥åŠå¦‚ä½•é€šéç‰¹å®šçš„æ²»ç™‚ä¾†æ¸›è¼•å…¶é€ æˆçš„å¿ƒè‚Œæå‚·ã€‚ç”±æ–¼ç›®å‰å°šç„¡é‡å°TTSçš„æœ‰æ•ˆæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚é¸æ“‡é¡¯å¾—å°¤ç‚ºé‡è¦ã€‚ç ”ç©¶ä¸­ï¼Œè˜¿è””ç¡«ç´ è¢«è¦–ç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ¿€æ´»åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„TTSç›¸é—œçš„å¿ƒè‚Œæå‚·ï¼Œé€™å¼•èµ·äº†ç ”ç©¶è€…çš„èˆˆè¶£ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬Takotsuboç—‡å€™ç¾¤ã€‚ç ”ç©¶çš„ä¸»è¦æ–¹æ³•æ˜¯è§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶å°æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¿ƒè‚Œçš„æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·æƒ…æ³ä»¥åŠéµæ­»äº¡çš„æ¨™è¨˜ç‰©ï¼Œä¸¦æ¯”è¼ƒäº†è˜¿è””ç¡«ç´ èˆ‡å…¶ä»–æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚Fer-1ï¼‰çš„æ•ˆæœï¼Œä»¥äº†è§£å…¶ç¨ç‰¹çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œå¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·ï¼Œä¸¦æŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚èˆ‡Fer-1ç›¸æ¯”ï¼Œè˜¿è””ç¡«ç´ ç¨ç‰¹åœ°æ¿€æ´»äº†Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºå…¶é›™é‡ä½œç”¨çš„æ½›åŠ›ã€‚ç„¶è€Œï¼Œç•¶Nrf2è¢«æŠ‘åˆ¶æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœæœƒæ¶ˆå¤±ï¼Œé€™å¼·èª¿äº†Nrf2åœ¨å…¶æ²»ç™‚æ•ˆæœä¸­çš„é—œéµè§’è‰²ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæ”¹å–„Takotsuboç—‡å€™ç¾¤çµæœçš„æ½›åœ¨æ²»ç™‚é¸æ“‡ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å¿ƒè‡Ÿç—…å«åšTakotsuboç—‡å€™ç¾¤ï¼Œé›–ç„¶è½èµ·ä¾†ä¸åš´é‡ï¼Œä½†å…¶å¯¦å¯èƒ½æœƒé€ æˆç”Ÿå‘½å±éšªï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°é€™ç¨®ç–¾ç—…æœ‰å¹«åŠ©å“¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿Takotsuboç—‡å€™ç¾¤çš„å¿ƒè‚Œæå‚·ã€‚ç ”ç©¶è€…å€‘ç”¨è€é¼ å’Œå¿ƒè‡Ÿç´°èƒä¾†æ¨¡æ“¬é€™ç¨®ç—…ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å¿ƒè‡Ÿçµæ§‹å’ŒåŠŸèƒ½çš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‡Ÿçš„å¥åº·ï¼Œé‚„èƒ½æ¸›å°‘æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡çš„æƒ…æ³ï¼Œé€™äº›éƒ½æ˜¯é€ æˆå¿ƒè‡Ÿæå‚·çš„åŸå› ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼š\n1. è˜¿è””ç¡«ç´ èƒ½å¢å¼·å¿ƒè‡Ÿçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ”¹å–„å¿ƒè‡ŸåŠŸèƒ½ã€‚\n2. å®ƒç¨ç‰¹åœ°æ¿€æ´»äº†èº«é«”çš„é˜²ç¦¦æ©Ÿåˆ¶ï¼Œå°æŠ—å¿ƒè‚Œæå‚·ã€‚\n3. ä¸éï¼Œç•¶é€™å€‹é˜²ç¦¦æ©Ÿåˆ¶è¢«æŠ‘åˆ¶æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœå°±æœƒæ¶ˆå¤±ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨å¿ƒè‡Ÿå¥åº·ä¸Šçš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the effects of sulforaphane on Takotsubo syndrome. The image should have a simple and clear design with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or heart cells, arrows or flow lines to indicate the experimental steps, and a section clearly stating the 'Main Results' such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºï¼Œå› ç‚ºè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰ç›Šè™•çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œå¯èƒ½å°äººé«”å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ çš„ä¾†æºä¸»è¦æ˜¯é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œé€™äº›è”¬èœåœ¨é£²é£Ÿä¸­è¶Šä¾†è¶Šå—åˆ°é‡è¦–ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡é€™äº›è”¬èœçš„å¥åº·åƒ¹å€¼ï¼Œé€²è€Œä¿ƒé€²ç–¾ç—…é é˜²ï¼Œç‰¹åˆ¥æ˜¯åœ¨èˆ‡ä»£è¬ç›¸é—œçš„ç–¾ç—…æ–¹é¢ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…èƒ½å¤ å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨é£Ÿç‰©ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿæä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰åŒ–ç‡ä¸€ç›´è¼ƒä½ï¼Œé€™ä½¿å¾—æˆ‘å€‘ç„¡æ³•å……åˆ†åˆ©ç”¨å…¶æ½›åœ¨çš„å¥åº·æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œä¾†æ”¹å–„é€™ç¨®è½‰åŒ–éç¨‹ï¼Œä¸¦æ·±å…¥äº†è§£ä¹³é…¸èŒåœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™ä¸åƒ…æ¶‰åŠå¾®ç”Ÿç‰©å­¸ï¼Œé‚„æ¶‰åŠç”Ÿç‰©åŒ–å­¸å’Œç‡Ÿé¤Šå­¸çš„äº¤å‰é ˜åŸŸï¼Œé¡¯ç¤ºå‡ºç ”ç©¶çš„å¤šæ¨£æ€§å’Œé‡è¦æ€§ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰åŒ–èƒ½åŠ›ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…èª¿æ•´äº†è‘¡è„ç³–çš„æ›¿ä»£æ¯”ç‡ï¼Œè§€å¯Ÿå…¶å°ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨ä¹³é…¸èŒçš„åŸºå› è¡¨é”è®ŠåŒ–ä¸Šï¼Œé€éè½‰éŒ„çµ„åˆ†æä¾†è©•ä¼°å…¶ä»£è¬è·¯å¾‘çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™äº›æ–¹æ³•ï¼Œèƒ½å¤ æ›´æ¸…æ¥šåœ°äº†è§£ä¹³é…¸èŒå¦‚ä½•æœ‰æ•ˆåœ°å°‡é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å‰é«”è½‰åŒ–ç‚ºæ´»æ€§æˆåˆ†ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆå½±éŸ¿ä¹³é…¸èŒçš„ä»£è¬è·¯å¾‘ï¼Œé€²è€Œæé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ä¸­æ¶‰åŠçš„é—œéµé…¶å’Œä»£è¬é€”å¾‘ï¼Œé€™äº›çµæœæœ‰åŠ©æ–¼æˆ‘å€‘æ›´æ·±å…¥åœ°ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºï¼Œå› ç‚ºè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰ç›Šè™•çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œå¯èƒ½å°äººé«”å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ çš„ä¾†æºä¸»è¦æ˜¯é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œé€™äº›è”¬èœåœ¨é£²é£Ÿä¸­è¶Šä¾†è¶Šå—åˆ°é‡è¦–ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡é€™äº›è”¬èœçš„å¥åº·åƒ¹å€¼ï¼Œé€²è€Œä¿ƒé€²ç–¾ç—…é é˜²ï¼Œç‰¹åˆ¥æ˜¯åœ¨èˆ‡ä»£è¬ç›¸é—œçš„ç–¾ç—…æ–¹é¢ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…èƒ½å¤ å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨é£Ÿç‰©ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·é£²é£Ÿæä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰åŒ–ç‡ä¸€ç›´è¼ƒä½ï¼Œé€™ä½¿å¾—æˆ‘å€‘ç„¡æ³•å……åˆ†åˆ©ç”¨å…¶æ½›åœ¨çš„å¥åº·æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œä¾†æ”¹å–„é€™ç¨®è½‰åŒ–éç¨‹ï¼Œä¸¦æ·±å…¥äº†è§£ä¹³é…¸èŒåœ¨é€™ä¸€éç¨‹ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™ä¸åƒ…æ¶‰åŠå¾®ç”Ÿç‰©å­¸ï¼Œé‚„æ¶‰åŠç”Ÿç‰©åŒ–å­¸å’Œç‡Ÿé¤Šå­¸çš„äº¤å‰é ˜åŸŸï¼Œé¡¯ç¤ºå‡ºç ”ç©¶çš„å¤šæ¨£æ€§å’Œé‡è¦æ€§ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€²ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰åŒ–èƒ½åŠ›ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶è€…èª¿æ•´äº†è‘¡è„ç³–çš„æ›¿ä»£æ¯”ç‡ï¼Œè§€å¯Ÿå…¶å°ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶ä¸»è¦é›†ä¸­åœ¨ä¹³é…¸èŒçš„åŸºå› è¡¨é”è®ŠåŒ–ä¸Šï¼Œé€éè½‰éŒ„çµ„åˆ†æä¾†è©•ä¼°å…¶ä»£è¬è·¯å¾‘çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›é€šéé€™äº›æ–¹æ³•ï¼Œèƒ½å¤ æ›´æ¸…æ¥šåœ°äº†è§£ä¹³é…¸èŒå¦‚ä½•æœ‰æ•ˆåœ°å°‡é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å‰é«”è½‰åŒ–ç‚ºæ´»æ€§æˆåˆ†ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹èª¿ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šèª¿ã€‚é€™è¡¨æ˜ï¼Œé€šéèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆå½±éŸ¿ä¹³é…¸èŒçš„ä»£è¬è·¯å¾‘ï¼Œé€²è€Œæé«˜è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ä¸­æ¶‰åŠçš„é—œéµé…¶å’Œä»£è¬é€”å¾‘ï¼Œé€™äº›çµæœæœ‰åŠ©æ–¼æˆ‘å€‘æ›´æ·±å…¥åœ°ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢è—è‘—ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„ç¥å¥‡ç‰©è³ªï¼Œå°æˆ‘å€‘çš„å¥åº·å¯èƒ½æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨å¦‚ä½•è®“æˆ‘å€‘æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®ç‰©è³ªã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯ï¼Œå¦‚ä½•æé«˜ä¸€ç¨®å«ä¹³é…¸èŒçš„å°å¹«æ‰‹ï¼Œè®“å®ƒå€‘æ›´æœ‰æ•ˆåœ°å°‡é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰åŒ–ç‚ºæˆ‘å€‘èƒ½å¸æ”¶çš„æ´»æ€§æˆåˆ†ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®ç‰¹æ®Šçš„å¯¦é©—æŠ€è¡“ï¼Œèª¿æ•´äº†åŸ¹é¤Šç’°å¢ƒä¸­çš„ç³–åˆ†æ¯”ä¾‹ï¼Œè§€å¯Ÿé€™å°ä¹³é…¸èŒçš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç•¶ç³–åˆ†çš„æ›¿ä»£æ¯”ç‡æé«˜æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬æœƒé™ä½ï¼Œè€Œæ°¨åŸºé…¸çš„ä»£è¬å‰‡æœƒå¢åŠ ã€‚é€™æ„å‘³è‘—ï¼Œé€éèª¿æ•´åŸ¹é¤Šæ¢ä»¶ï¼Œæˆ‘å€‘å¯ä»¥æœ‰æ•ˆåœ°æå‡è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œé€²ä¸€æ­¥äº†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„äº’å‹•ã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¥åº·æœ‰ç›Šï¼Œä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœã€‚\n2. ä¹³é…¸èŒåœ¨è½‰åŒ–è˜¿è””ç¡«ç´ çš„éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚\n3. èª¿æ•´åŸ¹é¤Šæ¢ä»¶å¯ä»¥æå‡è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ï¼Œé€™å°æœªä¾†çš„å¥åº·é£²é£Ÿæœ‰å¹«åŠ©ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the conversion of sulforaphane from broccoli using lactic acid bacteria. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating experimental steps, and a section highlighting the main results, such as changes in metabolic pathways.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2025 Dec",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ è„«æ°§é›ªè…éœ‰ç´ ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é¡¯è‘—é¢¨éšªã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—DONå¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•DONçš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥åº·ç›Šè™•ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†åŸºç¤ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6é›„æ€§å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“é¡å™¨å®˜é€²è¡Œå¯¦é©—ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”åˆ‡ç‰‡æŸ“è‰²ã€è¥¿æ–¹å°è·¡æ³•å’Œæµå¼ç´°èƒè¡“ç­‰ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡æº¶é…¶é«”åŠŸèƒ½æœ‰é—œï¼Œä¸¦ä¸”é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„çœŸèŒæ¯’ç´ è„«æ°§é›ªè…éœ‰ç´ ï¼ˆDONï¼‰ã€‚é€™ç¨®æ¯’ç´ åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å’Œå‹•ç‰©çš„å¥åº·æ§‹æˆäº†é¡¯è‘—é¢¨éšªã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œå¯èƒ½å°æŠ—DONå¼•èµ·çš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è„«æ°§é›ªè…éœ‰ç´ å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•DONçš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ·±å…¥äº†è§£å…¶å¦‚ä½•åœ¨ç´°èƒå±¤é¢ä¸Šç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥åº·ç›Šè™•ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶æä¾›äº†åŸºç¤ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6é›„æ€§å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“é¡å™¨å®˜é€²è¡Œå¯¦é©—ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”åˆ‡ç‰‡æŸ“è‰²ã€è¥¿æ–¹å°è·¡æ³•å’Œæµå¼ç´°èƒè¡“ç­‰ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¸›å°‘äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡æº¶é…¶é«”åŠŸèƒ½æœ‰é—œï¼Œä¸¦ä¸”é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­å¯èƒ½æ½›è—è‘—ä¸€äº›ä¸å¤ªå‹å–„çš„æ±è¥¿ï¼Œæ¯”å¦‚è„«æ°§é›ªè…éœ‰ç´ ï¼ˆDONï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸è¦‹çš„çœŸèŒæ¯’ç´ ï¼Œå°æˆ‘å€‘çš„å¥åº·æœ‰å½±éŸ¿ã€‚ä¸éï¼Œæœ€è¿‘çš„ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—é€™ç¨®æ¯’ç´ é€ æˆçš„è…¸é“æå‚·ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•ä¿è­·è…¸é“ï¼Œä¸¦äº†è§£å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…ä½¿ç”¨å°é¼ å’Œç´°èƒä¾†é€²è¡Œå¯¦é©—ï¼Œç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›è¼•DONçš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ”¹å–„è…¸é“çš„å¥åº·ã€‚\n\nå…·é«”ä¾†èªªï¼Œå¯¦é©—é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½æ¢å¾©è…¸é“çµ¨æ¯›çš„é«˜åº¦ï¼Œæ¸›å°‘ç´°èƒå‡‹äº¡ï¼Œä¸¦æ”¹å–„ç´°èƒçš„æ°§åŒ–é‚„åŸå¹³è¡¡ï¼Œé€™äº›éƒ½æ˜¯è…¸é“å¥åº·çš„é‡è¦æŒ‡æ¨™ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨èˆ‡ç´°èƒå…§çš„æº¶é…¶é«”åŠŸèƒ½æœ‰é—œï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚\n\nç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½å°æŠ—å¸¸è¦‹çš„çœŸèŒæ¯’ç´ ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ¸›è¼•è…¸é“æå‚·ï¼Œæ”¹å–„å¥åº·ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶é–‹å•Ÿäº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a simplified infographic that explains the experimental methods and main results of a study on the protective effects of sulforaphane against deoxynivalenol (DON) induced intestinal damage. Use a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice and cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒå°é€™äº›å£“åŠ›çš„æŠµæŠ—åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œåƒæ˜¯é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³ï¼Œé€²è€Œæ”¹å–„å‘¼å¸å¥åº·ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªï¼Œç‰¹åˆ¥é‡è¦ï¼Œå› ç‚ºä»–å€‘é¢è‡¨æ›´é«˜çš„è‚ºéƒ¨ç–¾ç—…é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œå¸ç…™å¦‚ä½•é€éæ°§åŒ–å£“åŠ›å½±éŸ¿è‚ºéƒ¨ç´°èƒçš„å¥åº·ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›æå®³ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°SIRT1é€™å€‹åŸºå› è¡¨é”çš„èª¿æ§ä½œç”¨ï¼Œé€™èˆ‡ç´°èƒçš„ç”Ÿå­˜å’ŒæŠµæŠ—å£“åŠ›çš„èƒ½åŠ›æœ‰é—œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ è‚ºéƒ¨ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©ï¼ˆCSEï¼‰å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†CSEä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†å°è‚ºéƒ¨çµ„ç¹”çš„å½±éŸ¿ï¼Œé€™äº›å¯¦é©—æŒçºŒäº†28å¤©ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•CSEå¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„è‚ºéƒ¨çµ„ç¹”çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰CSEå¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ï¼Œä¸¦ä¸”é€éæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶CSEå¼•èµ·çš„éµæ­»äº¡ï¼ŒåŒæ™‚é™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒå°é€™äº›å£“åŠ›çš„æŠµæŠ—åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œåƒæ˜¯é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³ï¼Œé€²è€Œæ”¹å–„å‘¼å¸å¥åº·ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸ç…™éœ§çš„äººä¾†èªªï¼Œç‰¹åˆ¥é‡è¦ï¼Œå› ç‚ºä»–å€‘é¢è‡¨æ›´é«˜çš„è‚ºéƒ¨ç–¾ç—…é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œå¸ç…™å¦‚ä½•é€éæ°§åŒ–å£“åŠ›å½±éŸ¿è‚ºéƒ¨ç´°èƒçš„å¥åº·ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•é€™äº›æå®³ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°SIRT1é€™å€‹åŸºå› è¡¨é”çš„èª¿æ§ä½œç”¨ï¼Œé€™èˆ‡ç´°èƒçš„ç”Ÿå­˜å’ŒæŠµæŠ—å£“åŠ›çš„èƒ½åŠ›æœ‰é—œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ è‚ºéƒ¨ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©ï¼ˆCSEï¼‰å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ çš„å¯¦é©—ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†CSEä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†å°è‚ºéƒ¨çµ„ç¹”çš„å½±éŸ¿ï¼Œé€™äº›å¯¦é©—æŒçºŒäº†28å¤©ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›è¼•CSEå¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„è‚ºéƒ¨çµ„ç¹”çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰CSEå¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ï¼Œä¸¦ä¸”é€éæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶CSEå¼•èµ·çš„éµæ­»äº¡ï¼ŒåŒæ™‚é™ä½éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…åƒ…æ˜¯ç¾å‘³çš„è”¬èœï¼å®ƒè£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œå¯èƒ½å°æˆ‘å€‘çš„è‚ºéƒ¨å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©å“¦ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å¸ç…™æ‰€é€ æˆçš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚å¸ç…™æœƒè®“æˆ‘å€‘çš„è‚ºéƒ¨æ‰¿å—å¾ˆå¤§çš„å£“åŠ›ï¼Œå°è‡´ç´°èƒå—æç”šè‡³è€åŒ–ã€‚è€Œç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦å¹«åŠ©æˆ‘å€‘çš„ç´°èƒæŠµæŠ—é€™äº›å£“åŠ›ã€‚\n\nä»–å€‘ä½¿ç”¨äº†äººé¡æ°£é“ç´°èƒå’Œå°é¼ ä¾†é€²è¡Œå¯¦é©—ï¼Œç™¼ç¾ç•¶ç´°èƒæ¥è§¸åˆ°å¸ç…™æå–ç‰©å¾Œï¼Œè˜¿è””ç¡«ç´ çš„åŠ å…¥èƒ½æœ‰æ•ˆæ¸›å°‘ç´°èƒçš„æå‚·å’Œè€åŒ–ï¼Œç”šè‡³æ”¹å–„è‚ºéƒ¨çš„å¥åº·ç‹€æ³ï¼\n\né€™é …ç ”ç©¶çš„çµæœå‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³ã€‚\n2. æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼ˆåƒæ˜¯é’èŠ±æ¤°èœï¼‰å°æ–¼å¸ç…™è€…ä¾†èªªç‰¹åˆ¥é‡è¦ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‚ºéƒ¨ç–¾ç—…é é˜²æä¾›äº†æ–°çš„æ€è·¯ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨è‚ºéƒ¨å¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹åšèµ·å§ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and key findings of a study on the protective effects of sulforaphane against smoking-induced lung damage. The design should be flat and simple, with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans, animals, or cells), arrows or flow lines to indicate the steps of the experiment, and a section that clearly highlights the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±ã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªï¼Œæ˜¯å¦èƒ½åœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚é€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå› ç‚ºå¦‚æœèƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡æ•´é«”å¥åº·ç‹€æ…‹ï¼Œæ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä»¥åŠå®ƒåœ¨æŠ—è€åŒ–éç¨‹ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å·²è¢«å»£æ³›æ‡‰ç”¨ï¼Œå› æ­¤ç ”ç©¶å…¶åœ¨çš®è†šè€åŒ–ä¸­çš„æ•ˆæœï¼Œå°‡æœ‰åŠ©æ–¼æ“´å±•å…¶æ‡‰ç”¨ç¯„åœï¼Œä¸¦æä¾›æ–°çš„æŠ—è€åŒ–ç­–ç•¥ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥äº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›ç›®æ¨™çš„èª¿æ§ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªèˆ‡apelinä¿¡è™Ÿé€šè·¯å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šæœƒå‡ºç¾è€åŒ–ç¾è±¡ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½å°è‡´èº«é«”çš„è„†å¼±ã€‚é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®åç‚ºè˜¿è””ç¡«ç´ çš„å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªï¼Œæ˜¯å¦èƒ½åœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢ç™¼æ®ä½œç”¨ã€‚é€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå› ç‚ºå¦‚æœèƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡æ•´é«”å¥åº·ç‹€æ…‹ï¼Œæ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä»¥åŠå®ƒåœ¨æŠ—è€åŒ–éç¨‹ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å·²è¢«å»£æ³›æ‡‰ç”¨ï¼Œå› æ­¤ç ”ç©¶å…¶åœ¨çš®è†šè€åŒ–ä¸­çš„æ•ˆæœï¼Œå°‡æœ‰åŠ©æ–¼æ“´å±•å…¶æ‡‰ç”¨ç¯„åœï¼Œä¸¦æä¾›æ–°çš„æŠ—è€åŒ–ç­–ç•¥ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥äº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å°é€™äº›ç›®æ¨™çš„èª¿æ§ä½œç”¨ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªèˆ‡apelinä¿¡è™Ÿé€šè·¯å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»é€™ä¸€ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ ä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šæœƒæ…¢æ…¢è®Šå¾—ä¸å¦‚å¾å‰ï¼Œé€™ä¸åƒ…å½±éŸ¿å¤–è§€ï¼Œé‚„å¯èƒ½è®“æˆ‘å€‘çš„èº«é«”è®Šå¾—è„†å¼±ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶é—œæ³¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œçœ‹çœ‹å®ƒæ˜¯å¦èƒ½å¹«åŠ©æˆ‘å€‘æ¸›ç·©çš®è†šè€åŒ–çš„éç¨‹ï¼\n\né€™é …ç ”ç©¶ä½¿ç”¨äº†18å€‹æœˆå¤§çš„å°é¼ ï¼Œæ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ä»–å€‘çµ¦é€™äº›å°é¼ è£œå……äº†è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿçš®è†šçµæ§‹å’Œå…ç–«ç³»çµ±çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šè®Šå¾—æ›´å¥åº·ï¼Œå…ç–«åŠŸèƒ½ä¹Ÿæœ‰äº†é¡¯è‘—æ”¹å–„ï¼\n\nç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰ä¸€äº›èˆ‡çš®è†šè€åŒ–ç›¸é—œçš„è›‹ç™½è³ªè®ŠåŒ–ï¼Œä¸¦ä¸”å¯èƒ½é€éæ¿€æ´»æŸäº›ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šçš„ç‹€æ…‹ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›ç·©çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è€åŒ–éç¨‹ï¼Œçµæœé¡¯ç¤ºçš®è†šå’Œå…ç–«åŠŸèƒ½æ”¹å–„ã€‚\n3. é€™ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment and main findings of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to show the experimental steps, and a section highlighting the main results, such as improvements in skin health and immune function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼æœªä¾†é–‹ç™¼ç›¸é—œçš„ä¿å¥é£Ÿå“æˆ–æ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€²ä¸€æ­¥ä¿ƒé€²æ•´é«”å¥åº·ï¼Œé€™å°æ–¼é é˜²èˆ‡è‚è‡Ÿå’Œå…ç–«ç³»çµ±ç›¸é—œçš„ç–¾ç—…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™å’Œè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå¤šç¨®å¥åº·å½±éŸ¿ï¼Œå› æ­¤äº†è§£å¦‚ä½•æ¸›å°‘å…¶æ¯’æ€§å½±éŸ¿å°æ–¼å…¬å…±å¥åº·éå¸¸é‡è¦ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆç·©è§£é€™äº›ä¸è‰¯å½±éŸ¿ï¼Œä¸¦æ”¹å–„ç›¸é—œçš„ç”Ÿç†åŠŸèƒ½ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„æš´éœ²å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†å„çµ„çš„è‚è‡ŸåŠŸèƒ½ã€å…ç–«åæ‡‰ä»¥åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†åŸºå› è¡¨é”å’Œè½‰éŒ„çµ„åˆ†æï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä¸¦å½±éŸ¿äº†ç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç„¶è€Œï¼Œè£œå……è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›ä¸è‰¯å½±éŸ¿å¾—åˆ°äº†ç·©è§£ï¼Œè‚è‡Ÿçš„ä»£è¬å¹³è¡¡å¾—ä»¥æ¢å¾©ï¼Œä¸¦ä¸”è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºæœ‰ç›ŠèŒçš„å¢åŠ å’Œæœ‰å®³èŒçš„æ¸›å°‘ã€‚é€™äº›ç™¼ç¾æ­ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æ–¹é¢çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„æ¯’æ€§ç·©è§£ç­–ç•¥æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼æœªä¾†é–‹ç™¼ç›¸é—œçš„ä¿å¥é£Ÿå“æˆ–æ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€²ä¸€æ­¥ä¿ƒé€²æ•´é«”å¥åº·ï¼Œé€™å°æ–¼é é˜²èˆ‡è‚è‡Ÿå’Œå…ç–«ç³»çµ±ç›¸é—œçš„ç–¾ç—…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™å’Œè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå¤šç¨®å¥åº·å½±éŸ¿ï¼Œå› æ­¤äº†è§£å¦‚ä½•æ¸›å°‘å…¶æ¯’æ€§å½±éŸ¿å°æ–¼å…¬å…±å¥åº·éå¸¸é‡è¦ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆç·©è§£é€™äº›ä¸è‰¯å½±éŸ¿ï¼Œä¸¦æ”¹å–„ç›¸é—œçš„ç”Ÿç†åŠŸèƒ½ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„æš´éœ²å¯¦é©—ã€‚é€™ä¸‰çµ„åˆ†åˆ¥æ˜¯å°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†å„çµ„çš„è‚è‡ŸåŠŸèƒ½ã€å…ç–«åæ‡‰ä»¥åŠè…¸é“å¾®ç”Ÿç‰©çš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†åŸºå› è¡¨é”å’Œè½‰éŒ„çµ„åˆ†æï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä¸¦å½±éŸ¿äº†ç›¸é—œåŸºå› çš„è¡¨é”ã€‚ç„¶è€Œï¼Œè£œå……è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›ä¸è‰¯å½±éŸ¿å¾—åˆ°äº†ç·©è§£ï¼Œè‚è‡Ÿçš„ä»£è¬å¹³è¡¡å¾—ä»¥æ¢å¾©ï¼Œä¸¦ä¸”è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºæœ‰ç›ŠèŒçš„å¢åŠ å’Œæœ‰å®³èŒçš„æ¸›å°‘ã€‚é€™äº›ç™¼ç¾æ­ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æ–¹é¢çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„æ¯’æ€§ç·©è§£ç­–ç•¥æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…è®“æˆ‘å€‘çš„èœæ›´ç¾å‘³ï¼Œé‚„å¯èƒ½å°å¥åº·æœ‰ç¥å¥‡çš„ä¿è­·ä½œç”¨ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¹«åŠ©æ¸›å°‘ä¸€ç¨®å«ä¸‰è‹¯éŒ«çš„ç’°å¢ƒæ±¡æŸ“ç‰©å°æˆ‘å€‘è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„å‚·å®³ã€‚é€™è½èµ·ä¾†æˆ–è¨±æœ‰é»è¤‡é›œï¼Œä½†è®“æˆ‘ä¾†å‘Šè¨´ä½ é€™é …ç ”ç©¶æ˜¯æ€éº¼é€²è¡Œçš„ï¼\n\nç ”ç©¶äººå“¡æŠŠé¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚å…¶ä¸­ä¸€çµ„åªæ¥è§¸ä¸‰è‹¯éŒ«ï¼Œå¦ä¸€çµ„å‰‡åœ¨æ¥è§¸ä¸‰è‹¯éŒ«çš„åŒæ™‚ï¼Œé‚„è£œå……äº†è˜¿è””ç¡«ç´ ã€‚çµæœç™¼ç¾ï¼Œä¸‰è‹¯éŒ«è®“è‚è‡Ÿå‡ºç¾æ¯’æ€§åæ‡‰ï¼Œä½†è£œå……è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›ä¸è‰¯å½±éŸ¿å¤§å¹…æ¸›å°‘ï¼Œè‚è‡Ÿçš„å¥åº·ç‹€æ³å¾—åˆ°äº†æ”¹å–„ï¼Œè…¸é“è£¡çš„å¥½èŒä¹Ÿè®Šå¤šäº†ï¼\n\né€™é …ç ”ç©¶çš„çµæœè®“æˆ‘å€‘çœ‹åˆ°äº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨å¥½è™•ï¼Œæœªä¾†å¯èƒ½æœƒæˆç‚ºä¿å¥é£Ÿå“çš„å¥½é¸æ“‡ï¼\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç’°å¢ƒæ±¡æŸ“ç‰©å°è‚è‡Ÿçš„å‚·å®³ã€‚  \n2. å®ƒèƒ½æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çµ„çš„å¥åº·ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ä¿å¥ç”¢å“é–‹ç™¼æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on a light background illustrating the experiment and results of a study on the protective effects of sulforaphane from broccoli. Include simplified icons of broccoli or sulforaphane, experimental subjects like fish, and arrows or flow lines to show the experimental steps. Add a section labeled 'Main Results' highlighting the protective effects and changes observed, such as improved liver health and increased beneficial bacteria.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„ä¸å¹³è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬éç¨‹ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†è‡¨åºŠæ²»ç™‚çš„ä¸€å€‹æ½›åœ¨é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„è…¸é“å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨æ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘è…¸é“ç‚ç—‡æ–¹é¢çš„æ©Ÿåˆ¶ï¼Œä¸¦ä¸”é—œæ³¨è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„è®ŠåŒ–å°é€™äº›æ•ˆæœçš„å½±éŸ¿ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶é ˜åŸŸï¼Œå› ç‚ºè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¥åº·ç‹€æ³èˆ‡å¤šç¨®è…¸é“ç–¾ç—…çš„ç™¼å±•å¯†åˆ‡ç›¸é—œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°è…¸é“ç‚ç—‡ã€‚éš¨å¾Œï¼Œç ”ç©¶è€…çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§å’Œçµè…¸ç‚ç—‡çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨æœªæ¨™çš„ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ï¼Œé€™æ¨£å¯ä»¥å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬çµ„å­¸åˆ†æä¸­ï¼Œç™¼ç¾èˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³æœ‰é¡¯è‘—è®ŠåŒ–ã€‚ç‰¹åˆ¥æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„è°·èƒ±ç”˜è‚½çš„ä»£è¬ï¼Œä¸¦æŠ‘åˆ¶èˆ‡ç‚ç—‡ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬éç¨‹ä¾†æ¸›è¼•è…¸é“ç‚ç—‡ï¼Œé€™ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„ä¸å¹³è¡¡æœ‰é—œï¼Œé€™å¯èƒ½æœƒå°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æ–°çš„æ²»ç™‚æ–¹å‘ã€‚é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬éç¨‹ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†è‡¨åºŠæ²»ç™‚çš„ä¸€å€‹æ½›åœ¨é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„è…¸é“å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨æ”¹å–„è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘è…¸é“ç‚ç—‡æ–¹é¢çš„æ©Ÿåˆ¶ï¼Œä¸¦ä¸”é—œæ³¨è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„è®ŠåŒ–å°é€™äº›æ•ˆæœçš„å½±éŸ¿ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶é ˜åŸŸï¼Œå› ç‚ºè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¥åº·ç‹€æ³èˆ‡å¤šç¨®è…¸é“ç–¾ç—…çš„ç™¼å±•å¯†åˆ‡ç›¸é—œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°è…¸é“ç‚ç—‡ã€‚éš¨å¾Œï¼Œç ”ç©¶è€…çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§å’Œçµè…¸ç‚ç—‡çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨æœªæ¨™çš„ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ï¼Œé€™æ¨£å¯ä»¥å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”åœ¨ä»£è¬çµ„å­¸åˆ†æä¸­ï¼Œç™¼ç¾èˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³æœ‰é¡¯è‘—è®ŠåŒ–ã€‚ç‰¹åˆ¥æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„è°·èƒ±ç”˜è‚½çš„ä»£è¬ï¼Œä¸¦æŠ‘åˆ¶èˆ‡ç‚ç—‡ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œä»£è¬éç¨‹ä¾†æ¸›è¼•è…¸é“ç‚ç—‡ï¼Œé€™ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…è®“æˆ‘å€‘çš„é¤æ¡Œæ›´ç¾å‘³ï¼Œé‚„å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œé€™æ˜¯ä¸€ç¨®æœƒå°è‡´è…¸é“ç™¼ç‚çš„ç–¾ç—…ã€‚ç ”ç©¶è€…å€‘ç”¨å°é¼ æ¨¡å‹æ¨¡æ“¬é€™ç¨®ç—…ç—‡ï¼Œç„¶å¾Œçµ¦å°é¼ åƒè˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹æœƒç™¼ç”Ÿä»€éº¼äº‹æƒ…ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å°é¼ çš„è…¸é“å¥åº·ï¼Œå¹«åŠ©ä¿®å¾©è…¸é“çš„é˜²è­·å±éšœï¼Œä¸¦æ¸›å°‘è…¸é“çš„ç‚ç—‡æƒ…æ³ã€‚æ›´æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ”¹è®Šè…¸é“å…§çš„å¾®ç”Ÿç‰©çµ„æˆï¼Œè®“è…¸é“ç’°å¢ƒè®Šå¾—æ›´å¹³è¡¡ï¼\n\né€™äº›ç™¼ç¾å°æ–¼æœªä¾†è…¸é“å¥åº·çš„è‡¨åºŠæ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œæˆ–è¨±è˜¿è””ç¡«ç´ å¯ä»¥æˆç‚ºæ”¹å–„è…¸é“å¥åº·çš„æ½›åœ¨é¸æ“‡ï¼\n\nğŸ”‘ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ã€‚\n2. å¯ä»¥æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œå°æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æœ‰æ½›åœ¨å¹«åŠ©ã€‚\n3. èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„ï¼Œä¿ƒé€²è…¸é“å¥åº·ã€‚  \nä¸€èµ·é—œæ³¨è…¸é“å¥åº·ï¼Œè®“æˆ‘å€‘çš„èº«é«”æ›´å¼·å£¯å§ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main findings of a study on the effects of sulforaphane. The image should have a flat design style with a light background and soft colors. Include simplified icons representing broccoli or sulforaphane, experimental subjects like mice, and arrows or flow lines indicating the steps of the experiment. There should also be a section labeled 'Main Findings' that highlights key results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ–°å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šå€‹ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½å°æŠ—è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­å±•ç¾å‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†æœ‰å¯èƒ½å°‡è˜¿è””ç¡«ç´ æ‡‰ç”¨æ–¼ç™Œç—‡æ²»ç™‚ï¼Œå°¤å…¶æ˜¯é‡å°æŸäº›ç‰¹å®šé¡å‹çš„ç™Œç—‡ï¼Œé€²ä¸€æ­¥çš„ç ”ç©¶å¯èƒ½æœƒæ­ç¤ºå…¶åœ¨è‡¨åºŠä¸Šçš„æ½›åœ¨æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰æ¨¡å‹ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œç‰¹åˆ¥æ˜¯å®ƒèˆ‡ç´ç±³è„‚è³ªé«”çš„çµåˆæ˜¯å¦èƒ½å¢å¼·å…¶ç™‚æ•ˆã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å…¶åˆ†ç‚ºå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬ä¸æ²»ç™‚ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ã€ä»¥åŠEACç´°èƒæ³¨å°„å¾Œçš„ä¸åŒçµ„åˆæ²»ç™‚ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œä¸»è¦è§€å¯Ÿè…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼æ¯”è¼ƒä¸åŒæ²»ç™‚æ–¹å¼çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜ç‰©æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAç¢ç‰‡åŠæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«æ€§ç‚ç—‡åæ‡‰ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€šéèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡ç›¸é—œåŸºå› çš„è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ–°å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šå€‹ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½å°æŠ—è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­å±•ç¾å‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ•ˆæœã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†æœ‰å¯èƒ½å°‡è˜¿è””ç¡«ç´ æ‡‰ç”¨æ–¼ç™Œç—‡æ²»ç™‚ï¼Œå°¤å…¶æ˜¯é‡å°æŸäº›ç‰¹å®šé¡å‹çš„ç™Œç—‡ï¼Œé€²ä¸€æ­¥çš„ç ”ç©¶å¯èƒ½æœƒæ­ç¤ºå…¶åœ¨è‡¨åºŠä¸Šçš„æ½›åœ¨æ‡‰ç”¨åƒ¹å€¼ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ çš„Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰æ¨¡å‹ä¸­çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œç‰¹åˆ¥æ˜¯å®ƒèˆ‡ç´ç±³è„‚è³ªé«”çš„çµåˆæ˜¯å¦èƒ½å¢å¼·å…¶ç™‚æ•ˆã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å…¶åˆ†ç‚ºå…­çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬ä¸æ²»ç™‚ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ã€ä»¥åŠEACç´°èƒæ³¨å°„å¾Œçš„ä¸åŒçµ„åˆæ²»ç™‚ã€‚æ²»ç™‚æŒçºŒ20å¤©ï¼Œä¸»è¦è§€å¯Ÿè…«ç˜¤é«”ç©ã€å­˜æ´»ç‡åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼æ¯”è¼ƒä¸åŒæ²»ç™‚æ–¹å¼çš„æ•ˆæœï¼Œä¸¦æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡åŠè…«ç˜¤æ¨™è¨˜ç‰©æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æ”¹å–„è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘DNAç¢ç‰‡åŠæ°§åŒ–å£“åŠ›ï¼Œä¸¦èª¿ç¯€å…¨èº«æ€§ç‚ç—‡åæ‡‰ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€šéèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡ç›¸é—œåŸºå› çš„è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å®Œæ•´æ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åƒ…å¯ä»¥è®“æ¹¯æ›´ç¾å‘³ï¼Œé‚„å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸Šæœ‰ä¸€ç•ªä½œç‚ºï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€™å€‹æˆåˆ†ï¼Œé€éèª¿ç¯€èº«é«”å…§çš„ä¿¡è™Ÿï¼Œå¯èƒ½æœ‰åŠ©æ–¼å°æŠ—è…«ç˜¤ç”Ÿé•·ã€‚ç ”ç©¶è€…å€‘åœ¨å°é¼ èº«ä¸Šé€²è¡Œå¯¦é©—ï¼Œæƒ³äº†è§£è˜¿è””ç¡«ç´ æ˜¯æ€éº¼é‹ä½œçš„ï¼Œç‰¹åˆ¥æ˜¯å®ƒè·Ÿç´ç±³è„‚è³ªé«”ï¼ˆå°é¡†ç²’ï¼‰çš„çµåˆæ˜¯å¦èƒ½è®“æ•ˆæœæ›´å¥½ã€‚  \n ç ”ç©¶ä¸­ï¼Œ90éš»å°é¼ è¢«åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œæ¥å—ä¸åŒçš„è™•ç†ï¼ŒåŒ…æ‹¬ä¸æ²»ç™‚ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ æˆ–æ˜¯ç´ç±³è„‚è³ªé«”ï¼Œé‚„æœ‰å…¶ä»–çš„çµ„åˆæ²»ç™‚ã€‚å¯¦é©—æŒçºŒäº†20å¤©ï¼Œä¸»è¦è§€å¯Ÿè…«ç˜¤çš„å¤§å°ã€æ´»å­˜ç‡å’Œä¸€äº›ç”Ÿç‰©æ¨™è¨˜ã€‚  \n æœ€å¾Œçš„çµæœè®“äººé©šå–œï¼è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤å¤§å°å’Œæ”¹å–„è‚è‡Ÿå¥åº·æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´å¥½ï¼Œé‚„èƒ½æ¸›å°‘æ°§åŒ–å£“åŠ›å’Œèª¿ç¯€å…¨èº«çš„ç‚ç—‡åæ‡‰ã€‚é€™æ„å‘³è‘—ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨ç™Œç—‡æ²»ç™‚ä¸­å¯èƒ½æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼  \n ç¸½çµä¸€ä¸‹ï¼š  \n 1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ—è…«ç˜¤ç”Ÿé•·ã€‚  \n 2. èˆ‡ç´ç±³è„‚è³ªé«”çµåˆèƒ½æé«˜å…¶ç™‚æ•ˆã€‚  \n 3. ç ”ç©¶é¡¯ç¤ºå…¶å°è‚è‡Ÿå¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane (SFN) and its effects on tumor growth. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects and changes observed. Use a light background with soft colors and a clear, informative style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ï¼Œå› ç‚ºç›®å‰å°èƒƒç™Œçš„æ²»ç™‚é¸æ“‡ä»ç„¶æœ‰é™ã€‚",
    "para3": "ç ”ç©¶è€…åœ¨å¯¦é©—ä¸­ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„æ¨¡å‹ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯å°äººé¡å¥åº·çš„ä¸€å¤§å¨è„…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä¸¦æ‰¾å‡ºå…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ï¼Œå› ç‚ºç›®å‰å°èƒƒç™Œçš„æ²»ç™‚é¸æ“‡ä»ç„¶æœ‰é™ã€‚\n\nç ”ç©¶è€…åœ¨å¯¦é©—ä¸­ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„æ¨¡å‹ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠé€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œé€²è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘æ¯å¤©åƒçš„è˜¿è””å’Œé’èŠ±æ¤°èœè£¡ï¼Œå…¶å¯¦è—è‘—ä¸€ç¨®å«ã€Œè˜¿è””ç¡«ç´ ã€çš„ç¥å¥‡æˆåˆ†ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨é€™ç¨®æˆåˆ†å°èƒƒç™Œçš„å½±éŸ¿ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚å¸¶ä¾†æ–°å¸Œæœ›ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸åŒçš„å¯¦é©—æ¨¡å‹ï¼Œä¾†æ‰¾å‡ºé€™ç¨®æˆåˆ†çš„æŠ—è…«ç˜¤æ©Ÿåˆ¶ã€‚ä»–å€‘é€²è¡ŒåŸºå› åˆ†æï¼Œç™¼ç¾äº†ä¸€äº›èˆ‡è˜¿è””ç¡«ç´ ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ï¼Œé€™äº›RNAåœ¨ç™Œç´°èƒä¸­çš„è¡¨ç¾èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ï¼Œä¸¦é™ä½ä¸€ç¨®åå«CKMT2-AS1çš„RNAçš„è¡¨é”ã€‚ç•¶é€™ç¨®RNAè¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»éƒ½é¡¯è‘—æ¸›å°‘ï¼é€™æ„å‘³è‘—ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æœªä¾†æˆç‚ºèƒƒç™Œæ²»ç™‚çš„ä¸€å€‹é‡è¦è§’è‰²ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æŠ‘åˆ¶èƒƒç™Œç´°èƒçš„å¢é•·ã€‚\n2. CKMT2-AS1çš„è¡¨é”èˆ‡æ‚£è€…ç”Ÿå­˜ç‡æœ‰é—œã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„èƒƒç™Œæ²»ç™‚æä¾›äº†æ–°æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the effects of sulforaphane from broccoli and radishes on stomach cancer. Include simplified illustrations of radishes or broccoli, human or animal subjects, and arrows or flow lines to indicate the experimental steps. Add a section labeled 'Main Results' highlighting protective effects and changes observed in cancer cell behavior.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡æ‚£è€…æä¾›æ–°çš„é£²é£Ÿè£œå……é¸æ“‡ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›å°‹æ±‚éè—¥ç‰©ç™‚æ³•çš„å®¶åº­ä¾†èªªï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»æœ‰çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶çš„ç™¼ç¾ç‚ºæœªä¾†çš„ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨æä¾›äº†é‡è¦çš„åŸºç¤ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œé€²è€Œæå‡ä»–å€‘çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ­ç¤ºå…¶æ½›åœ¨çš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼è‡ªé–‰ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•å°æ–¼æ‚£è€…åŠå…¶å®¶åº­ä¾†èªªè‡³é—œé‡è¦ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„æ„ç¾©ä¸è¨€è€Œå–»ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œäº†çµ±åˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚æœ€çµ‚ï¼Œå…­é …è©¦é©—å…±æ¶‰åŠ333ååƒèˆ‡è€…è¢«ç´å…¥çµ±åˆåˆ†æã€‚ç ”ç©¶ä¸­ï¼Œåƒèˆ‡è€…æ¥å—äº†ä¸åŒæ™‚é•·çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘çµ„é€²è¡Œæ¯”è¼ƒï¼Œä»¥è©•ä¼°å…¶å°ç¤¾äº¤åæ‡‰é‡è¡¨çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‹ç”¨äº†ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ç­‰æ–¹æ³•ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œå‡é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ åœ¨ä½¿ç”¨ä¸Šå¯èƒ½æ˜¯å®‰å…¨çš„ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æé‚„ç¢ºå®šäº†10å€‹èˆ‡è‡ªé–‰ç—‡ç›¸é—œçš„æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡æ‚£è€…æä¾›æ–°çš„é£²é£Ÿè£œå……é¸æ“‡ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›å°‹æ±‚éè—¥ç‰©ç™‚æ³•çš„å®¶åº­ä¾†èªªï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é›–ç„¶è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä»æœ‰çˆ­è­°ï¼Œä½†é€™é …ç ”ç©¶çš„ç™¼ç¾ç‚ºæœªä¾†çš„ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨æä¾›äº†é‡è¦çš„åŸºç¤ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œé€²è€Œæå‡ä»–å€‘çš„ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ­ç¤ºå…¶æ½›åœ¨çš„è—¥ç†æ©Ÿåˆ¶ã€‚ç”±æ–¼è‡ªé–‰ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç¥ç¶“ç™¼å±•éšœç¤™ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„è¼”åŠ©ç™‚æ³•å°æ–¼æ‚£è€…åŠå…¶å®¶åº­ä¾†èªªè‡³é—œé‡è¦ï¼Œå› æ­¤é€™é …ç ”ç©¶çš„æ„ç¾©ä¸è¨€è€Œå–»ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œä¸¦ä½¿ç”¨Review Manager 5.4é€²è¡Œäº†çµ±åˆåˆ†æå’Œåå€šé¢¨éšªè©•ä¼°ã€‚æœ€çµ‚ï¼Œå…­é …è©¦é©—å…±æ¶‰åŠ333ååƒèˆ‡è€…è¢«ç´å…¥çµ±åˆåˆ†æã€‚ç ”ç©¶ä¸­ï¼Œåƒèˆ‡è€…æ¥å—äº†ä¸åŒæ™‚é•·çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘çµ„é€²è¡Œæ¯”è¼ƒï¼Œä»¥è©•ä¼°å…¶å°ç¤¾äº¤åæ‡‰é‡è¡¨çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é‹ç”¨äº†ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ç­‰æ–¹æ³•ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œå‡é¡¯è‘—é™ä½äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ åœ¨ä½¿ç”¨ä¸Šå¯èƒ½æ˜¯å®‰å…¨çš„ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æé‚„ç¢ºå®šäº†10å€‹èˆ‡è‡ªé–‰ç—‡ç›¸é—œçš„æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å¤©ç„¶æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œæœ€è¿‘åœ¨è‡ªé–‰ç—‡ç ”ç©¶ä¸­å¼•èµ·äº†å¤§å®¶çš„æ³¨æ„ï¼é€™ç¨®æˆåˆ†ä¸»è¦ä¾†è‡ªé’èŠ±èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£å®ƒæ˜¯å¦èƒ½å¹«åŠ©è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æ‚£è€…æ”¹å–„ç¤¾äº¤èƒ½åŠ›ã€‚\n\né€™é …ç ”ç©¶å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†333ååƒèˆ‡è€…ã€‚ä»–å€‘æ¥å—äº†ä¸åŒæ™‚é•·çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œä¸¦èˆ‡å®‰æ…°åŠ‘çµ„é€²è¡Œæ¯”è¼ƒï¼Œä»¥è©•ä¼°å°ç¤¾äº¤åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘é‚„æ¢è¨äº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™æ¨£çš„ç ”ç©¶æ–¹å¼è®“æˆ‘å€‘å°é€™ç¨®æˆåˆ†çš„æ½›åŠ›æœ‰äº†æ›´æ·±å…¥çš„äº†è§£ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯4-5é€±é‚„æ˜¯8-10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼Œéƒ½é¡¯è‘—æ”¹å–„äº†åƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å°è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›æœ‰å¹«åŠ©ã€‚è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨ï¼Œé¡¯ç¤ºå®ƒåœ¨ä½¿ç”¨ä¸Šå¯èƒ½æ˜¯å®‰å…¨çš„ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚  \n2. ç ”ç©¶é¡¯ç¤ºä½¿ç”¨è˜¿è””ç¡«ç´ çš„éç¨‹ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—å‰¯ä½œç”¨ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„ç›¸é—œç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å¥ å®šäº†åŸºç¤ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane and autism spectrum disorder (ASD). Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans or cells), and arrows or flow lines to indicate the steps of the experiment. Additionally, include a section labeled 'Main Results' highlighting the protective effects observed and the direction of changes.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2025 Nov",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œç ”ç©¶é¡¯ç¤ºå¯ä»¥å¢åŠ é’èŠ±æ¤°èœä¸­è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å¯èƒ½å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿå’Œå¢å¼·å…ç–«ç³»çµ±çš„äººå€‘ä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½å°æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·æ½›åŠ›ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œé‚„èƒ½ç‚ºé£Ÿå“åŠ å·¥æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œé€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­é‚„æ¡ç”¨äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“ä¾†è™•ç†èŠ½ç²‰ï¼Œä»¥è©•ä¼°å…¶å“è³ªã€‚ç ”ç©¶è€…æ¸¬é‡äº†é’èŠ±æ¤°èœèŠ½ä¸­è˜¿è””ç¡«ç´ ã€ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ï¼Œä¸¦åˆ†æäº†é€™äº›æˆåˆ†çš„è®ŠåŒ–ï¼Œå¾è€Œäº†è§£ä¸åŒè™•ç†æ–¹æ³•å°ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—æå‡ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†è¼ƒé«˜çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½å«é‡ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨åœ¨é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œç ”ç©¶é¡¯ç¤ºå¯ä»¥å¢åŠ é’èŠ±æ¤°èœä¸­è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å¯èƒ½å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿå’Œå¢å¼·å…ç–«ç³»çµ±çš„äººå€‘ä¾†èªªï¼Œæ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½å°æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·æ½›åŠ›ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œé‚„èƒ½ç‚ºé£Ÿå“åŠ å·¥æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œé€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­é‚„æ¡ç”¨äº†çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“ä¾†è™•ç†èŠ½ç²‰ï¼Œä»¥è©•ä¼°å…¶å“è³ªã€‚ç ”ç©¶è€…æ¸¬é‡äº†é’èŠ±æ¤°èœèŠ½ä¸­è˜¿è””ç¡«ç´ ã€ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ï¼Œä¸¦åˆ†æäº†é€™äº›æˆåˆ†çš„è®ŠåŒ–ï¼Œå¾è€Œäº†è§£ä¸åŒè™•ç†æ–¹æ³•å°ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—æå‡ã€‚æ­¤å¤–ï¼Œé€™ç¨®è™•ç†é‚„å¢å¼·äº†é…µç´ æ´»æ€§ï¼Œä¸¦ä¿ƒé€²äº†æ»²é€èª¿ç¯€å› å­çš„ä¸Šèª¿ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†è¼ƒé«˜çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½å«é‡ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„è¯åˆæ‡‰ç”¨åœ¨é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡é¢è—è‘—ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†å—ï¼Ÿé‚£å°±æ˜¯è˜¿è””ç¡«ç´ ï¼é€™é …ç ”ç©¶è®“æˆ‘å€‘ç™¼ç¾ï¼Œé€éä¸€äº›ç‰¹åˆ¥çš„è™•ç†æ–¹æ³•ï¼Œé’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼å¯ä»¥å¤§å¹…æå‡ï¼Œå°¤å…¶æ˜¯å°å¥åº·æœ‰ç›Šçš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é’èŠ±æ¤°èœèŠ½ï¼Œä½¿ç”¨äº†ä¸€ç¨®å«åšç”²ç¡«æ°¨é…¸-è”—ç³–çš„è™•ç†æ–¹å¼ï¼Œä¾†çœ‹çœ‹é€™å°ç‡Ÿé¤Šæˆåˆ†æœ‰ä»€éº¼å½±éŸ¿ã€‚ä»–å€‘é‚„åˆ©ç”¨çœŸç©ºå†·å‡ä¹¾ç‡¥æŠ€è¡“ä¾†ä¿ç•™èŠ½ç²‰çš„å“è³ªã€‚çµæœç™¼ç¾ï¼Œé€™ç¨®è™•ç†è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡å¢åŠ äº†316.30%ï¼Œè€Œä¸”å…¶ä»–å¥åº·æˆåˆ†ä¹Ÿæœ‰é¡¯è‘—æå‡ï¼é€™ä¸åƒ…è®“é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ›´é«˜ï¼Œé‚„å¯èƒ½å¹«åŠ©æˆ‘å€‘é–‹ç™¼å‡ºæ›´å¥½çš„åŠŸèƒ½æ€§é£Ÿå“ã€‚ ä¾†çœ‹çœ‹é€™äº›é‡é»ï¼š\n1. è”—ç³–è™•ç†é¡¯è‘—æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥ä¿ç•™äº†é«˜å«é‡çš„è˜¿è””ç¡«ç´ ã€‚\n3. è˜¿è””ç¡«ç´ å°æŸäº›ç´°èŒæœ‰æŠ—èŒä½œç”¨ï¼Œè®“æˆ‘å€‘çš„å¥åº·æ›´æœ‰ä¿éšœï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on broccoli sprouts. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results (such as significant increases in certain nutrients and protective effects). Use a light background with soft colors for a scientific and informative look.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "journal": "ACS applied bio materials",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½å½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦å¸Œæœ›èƒ½æ‰¾åˆ°é é˜²æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–°æ–¹æ³•ã€‚é€éæ”¹å–„å…ç–«åæ‡‰ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æå‡ç§»æ¤æˆåŠŸç‡ï¼Œå°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤ç‰©å­˜æ´»ä¸­çš„ä½œç”¨ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£å¦‚ä½•æ”¹å–„å™¨å®˜ç§»æ¤çš„çµæœï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†çš®è†šç§»æ¤æ¨¡å‹çš„å°é¼ ï¼Œç ”ç©¶è€…å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆä¸€ç¨®ç†±æ•æ€§èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ‰‹è¡“ä¸­ã€‚é€™ç¨®æ°´å‡è† çš„çµ„æˆå’Œç‰¹æ€§ç¶“éè©³ç´°çš„åˆ†æï¼Œä¸¦ä¸”åœ¨å°é¼ èº«ä¸Šé€²è¡Œäº†ç§»æ¤æ‰‹è¡“ï¼Œä»¥è§€å¯Ÿå…¶å°ç§»æ¤ç‰©å­˜æ´»çš„å½±éŸ¿ã€‚å¯¦é©—é‚„åŒ…æ‹¬äº†å°å…ç–«ç´°èƒçš„ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®è™•ç†ä¸æœƒå°ç´°èƒé€ æˆå‚·å®³ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œèˆ‡æœªè™•ç†çš„å°é¼ ç›¸æ¯”ï¼Œç§»æ¤ç‰©çš„å­˜æ´»ç‡é”åˆ°80%ä»¥ä¸Šã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ åœ¨çš®è†šç§»æ¤éƒ¨ä½çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æ¸›å°‘äº†å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©äº†æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„ç ”ç©¶ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½å½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦å¸Œæœ›èƒ½æ‰¾åˆ°é é˜²æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–°æ–¹æ³•ã€‚é€éæ”¹å–„å…ç–«åæ‡‰ï¼Œé€™å¯èƒ½æœ‰åŠ©æ–¼æå‡ç§»æ¤æˆåŠŸç‡ï¼Œå°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒåœ¨ç§»æ¤ç‰©å­˜æ´»ä¸­çš„ä½œç”¨ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£å¦‚ä½•æ”¹å–„å™¨å®˜ç§»æ¤çš„çµæœï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†çš®è†šç§»æ¤æ¨¡å‹çš„å°é¼ ï¼Œç ”ç©¶è€…å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸æ··åˆï¼Œè£½æˆä¸€ç¨®ç†±æ•æ€§èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼å°é¼ çš„çš®è†šç§»æ¤æ‰‹è¡“ä¸­ã€‚é€™ç¨®æ°´å‡è† çš„çµ„æˆå’Œç‰¹æ€§ç¶“éè©³ç´°çš„åˆ†æï¼Œä¸¦ä¸”åœ¨å°é¼ èº«ä¸Šé€²è¡Œäº†ç§»æ¤æ‰‹è¡“ï¼Œä»¥è§€å¯Ÿå…¶å°ç§»æ¤ç‰©å­˜æ´»çš„å½±éŸ¿ã€‚å¯¦é©—é‚„åŒ…æ‹¬äº†å°å…ç–«ç´°èƒçš„ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®è™•ç†ä¸æœƒå°ç´°èƒé€ æˆå‚·å®³ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œèˆ‡æœªè™•ç†çš„å°é¼ ç›¸æ¯”ï¼Œç§»æ¤ç‰©çš„å­˜æ´»ç‡é”åˆ°80%ä»¥ä¸Šã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„å°é¼ åœ¨çš®è†šç§»æ¤éƒ¨ä½çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æ¸›å°‘äº†å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©äº†æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„ç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS applied bio materialsã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œâœ¨ ä½ çŸ¥é“è˜¿è””ä¹Ÿèƒ½å¹«åŠ©å™¨å®˜ç§»æ¤å—ï¼Ÿâœ¨ åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰å¸¸å¸¸æ˜¯ä¸€å€‹é ­ç—›çš„å•é¡Œï¼Œå½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªå¯èƒ½å°å…ç–«ç³»çµ±æœ‰æ­£é¢çš„å½±éŸ¿ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°é é˜²æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–°æ–¹æ³•ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤çš„å¯¦é©—ä¸­ã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆçš„æ°´å‡è† æ‡‰ç”¨æ–¼ç§»æ¤æ‰‹è¡“ï¼Œä¸¦è§€å¯Ÿå®ƒå°ç§»æ¤ç‰©çš„å½±éŸ¿ã€‚\n\nå¯¦é©—çµæœé¡¯ç¤ºï¼Œä½¿ç”¨è˜¿è””ç¡«ç´ çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„å­˜æ´»ç‡é”åˆ°80%ä»¥ä¸Šï¼Œæ˜é¡¯é«˜æ–¼æœªè™•ç†çš„å°é¼ ï¼è€Œä¸”ï¼Œæ¥å—è˜¿è””ç¡«ç´ çš„å°é¼ åœ¨ç§»æ¤éƒ¨ä½çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚\n\nğŸ” é€™äº›ç ”ç©¶çµæœå‘Šè¨´æˆ‘å€‘ï¼š\n1ï¸âƒ£ è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æå‡å™¨å®˜ç§»æ¤çš„æˆåŠŸç‡ã€‚\n2ï¸âƒ£ å®ƒå¯èƒ½æ¸›å°‘å…ç–«ç³»çµ±çš„éåº¦åæ‡‰ã€‚\n3ï¸âƒ£ é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·ç®¡ç†æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on the effects of sulforaphane from radishes on acute rejection in organ transplantation. Include simplified illustrations of radishes or sulforaphane, a mouse as the experimental subject, and arrows or flow lines to indicate the experimental steps. Highlight a section labeled 'Main Results' showing the protective effects and increased survival rates of the grafts.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "journal": "Discover oncology",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œä¸¦å¯èƒ½ç‚ºå¥åº·å’Œç–¾ç—…é é˜²å¸¶ä¾†æ–°çš„å•Ÿç¤ºã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©äººå€‘æŠµæŠ—ç™Œç—‡åŠå…¶ä»–ç›¸é—œç–¾ç—…ã€‚",
    "para2": "é€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œé€²è€Œå½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚é€™äº›ä¿¡è™Ÿåˆ†å­æ¶‰åŠå¤šå€‹é‡è¦çš„ç”Ÿç‰©éç¨‹ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­çš„é—œéµå› ç´ ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ï¼Œä»¥åŠèˆ‡ç´°èƒå­˜æ´»ç›¸é—œçš„è›‹ç™½è³ªå¦‚Baxå’ŒBcl-2ã€‚é€™é …å›é¡§æ€§ç ”ç©¶æ•´åˆäº†ç¾æœ‰çš„æ–‡ç»ï¼Œä¸¦æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨è˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„æ½›åœ¨å„ªå‹¢ï¼Œæä¾›äº†å°å…¶æ©Ÿåˆ¶çš„å…¨é¢ç†è§£ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å…¶æ‡‰ç”¨å¯èƒ½æœƒå—åˆ°ç´ç±³æŠ€è¡“çš„é€²ä¸€æ­¥å¢å¼·ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ç¯„åœï¼Œä¸¦ä¸æ„å‘³è‘—å®ƒä¸€å®šèƒ½æ²»ç™’ç™Œç—‡ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œä¸¦å¯èƒ½ç‚ºå¥åº·å’Œç–¾ç—…é é˜²å¸¶ä¾†æ–°çš„å•Ÿç¤ºã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ç”Ÿç‰©é€”å¾‘ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©äººå€‘æŠµæŠ—ç™Œç—‡åŠå…¶ä»–ç›¸é—œç–¾ç—…ã€‚\n\né€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œé€²è€Œå½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚é€™äº›ä¿¡è™Ÿåˆ†å­æ¶‰åŠå¤šå€‹é‡è¦çš„ç”Ÿç‰©éç¨‹ï¼ŒåŒ…æ‹¬è¡€ç®¡ç”Ÿæˆã€ç´°èƒå‡‹äº¡ã€ç´°èƒé€±æœŸåœæ»¯ã€è½‰ç§»ä»¥åŠç‚ç—‡åæ‡‰ç­‰ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­çš„é—œéµå› ç´ ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç‚ç—‡ä»‹è³ªã€åŠèƒ±å¤©å†¬é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ï¼Œä»¥åŠèˆ‡ç´°èƒå­˜æ´»ç›¸é—œçš„è›‹ç™½è³ªå¦‚Baxå’ŒBcl-2ã€‚é€™é …å›é¡§æ€§ç ”ç©¶æ•´åˆäº†ç¾æœ‰çš„æ–‡ç»ï¼Œä¸¦æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨è˜¿è””ç¡«ç´ æ‡‰ç”¨ä¸­çš„æ½›åœ¨å„ªå‹¢ï¼Œæä¾›äº†å°å…¶æ©Ÿåˆ¶çš„å…¨é¢ç†è§£ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œä¸¦ä¸”å…¶æ‡‰ç”¨å¯èƒ½æœƒå—åˆ°ç´ç±³æŠ€è¡“çš„é€²ä¸€æ­¥å¢å¼·ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ç¯„åœï¼Œä¸¦ä¸æ„å‘³è‘—å®ƒä¸€å®šèƒ½æ²»ç™’ç™Œç—‡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶éš±è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œå®ƒä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œç§‘å­¸å®¶å€‘å°å®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨è¶Šä¾†è¶Šæ„Ÿèˆˆè¶£ã€‚é€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ï¼Œå°¤å…¶æ˜¯å®ƒå¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ã€‚é€™äº›ä¿¡è™Ÿåˆ†å­å°æ–¼ç™Œç—‡çš„ç™¼å±•è‡³é—œé‡è¦ï¼Œåƒæ˜¯å½±éŸ¿ç´°èƒçš„æ­»äº¡ã€å¢æ®–å’Œç‚ç—‡åæ‡‰ç­‰ã€‚  \n\nç ”ç©¶è€…å€‘å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼Œé€™äº›æ¨™è¨˜ç‰©èˆ‡ç‚ç—‡ã€ç´°èƒå­˜æ´»ç­‰æœ‰é—œã€‚ä»–å€‘ä¹Ÿæ¢è¨äº†ç´ç±³æŠ€è¡“åœ¨é€™æ–¹é¢çš„æ½›åœ¨å„ªå‹¢ï¼Œè®“æˆ‘å€‘æ›´æ·±å…¥ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚  \n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œæœªä¾†çš„ç ”ç©¶å¯èƒ½æœƒé€²ä¸€æ­¥æå‡å®ƒçš„æ‡‰ç”¨æ½›åŠ›ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºå®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœã€‚  \n\nâœ¨é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ã€‚  \n2. ç ”ç©¶æ¢è¨äº†å®ƒå¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œå­˜æ´»ã€‚  \n3. éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ç¯„åœã€‚",
    "image_prompt": "Create a flat design infographic on a light background to explain the experiment and main findings of a study on sulforaphane. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to indicate the steps of the experiment. Add a section labeled 'Main Findings' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "journal": "BMC psychiatry",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆä¾‹å¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œå·²è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ•ˆæœï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç²¾ç¥åˆ†è£‚ç—‡çš„ä¸»è¦ç—‡ç‹€å’ŒèªçŸ¥åŠŸèƒ½ã€‚é€™æ˜¯ç¬¬ä¸€å€‹ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œå°ˆé–€é‡å°è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç²¾ç¥ç–¾ç—…ä¸­çš„æ‡‰ç”¨ï¼Œä¸¦ä¸”è©•ä¼°å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦é¸æ“‡äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æœ€çµ‚ç´å…¥äº†å››é …ç ”ç©¶ï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨ï¼Œæ­¤å¤–é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœ€æ–°çš„éš¨è¨ªä¸­å°PANSSç¸½åˆ†å’Œæ­£æ€§ç—‡ç‹€çš„æ”¹å–„ä¸¦ä¸é¡¯è‘—ï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ã€‚ä¸€èˆ¬çš„ç²¾ç¥ç—…ç†å­¸è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œä¸”åœ¨ä»£è¬æ¨™è¨˜æ–¹é¢ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ç­‰å‡æœ‰é¡¯è‘—é™ä½ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çµ„çš„ä¸­æ–·ç‡è¼ƒä½ã€‚å„˜ç®¡é€™äº›çµæœæä¾›äº†åˆæ­¥çš„è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™å’Œç•°è³ªæ€§ï¼Œç ”ç©¶çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼ˆä¾‹å¦‚é’èŠ±æ¤°èœï¼‰çš„åŒ–åˆç‰©ï¼Œå·²è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æå°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ•ˆæœï¼Œé€™å°æ–¼å°‹æ±‚æ–°ç™‚æ³•çš„æ‚£è€…ä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£é€™ç¨®åŒ–åˆç‰©æ˜¯å¦èƒ½æ”¹å–„æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯é‡å°ç²¾ç¥åˆ†è£‚ç—‡çš„ä¸»è¦ç—‡ç‹€å’ŒèªçŸ¥åŠŸèƒ½ã€‚é€™æ˜¯ç¬¬ä¸€å€‹ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œå°ˆé–€é‡å°è˜¿è””ç¡«ç´ åœ¨é€™ç¨®ç²¾ç¥ç–¾ç—…ä¸­çš„æ‡‰ç”¨ï¼Œä¸¦ä¸”è©•ä¼°å…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦é¸æ“‡äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æœ€çµ‚ç´å…¥äº†å››é …ç ”ç©¶ï¼Œæ¶‰åŠ369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™åŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨ï¼Œæ­¤å¤–é‚„è€ƒé‡äº†èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æœ€æ–°çš„éš¨è¨ªä¸­å°PANSSç¸½åˆ†å’Œæ­£æ€§ç—‡ç‹€çš„æ”¹å–„ä¸¦ä¸é¡¯è‘—ï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ã€‚ä¸€èˆ¬çš„ç²¾ç¥ç—…ç†å­¸è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œä¸”åœ¨ä»£è¬æ¨™è¨˜æ–¹é¢ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ç­‰å‡æœ‰é¡¯è‘—é™ä½ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ çµ„çš„ä¸­æ–·ç‡è¼ƒä½ã€‚å„˜ç®¡é€™äº›çµæœæä¾›äº†åˆæ­¥çš„è¦‹è§£ï¼Œä½†ç”±æ–¼æ•¸æ“šæœ‰é™å’Œç•°è³ªæ€§ï¼Œç ”ç©¶çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC psychiatryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ€ ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›è”¬èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„ç²¾ç¥å¥åº·æœ‰å¹«åŠ©ï¼é€™æ¬¡æˆ‘å€‘ä¾†èŠèŠä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡æˆåˆ†ï¼Œå®ƒä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘çš„è”¬èœã€‚æœ€è¿‘æœ‰ç ”ç©¶å°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„å½±éŸ¿ï¼Œé€™å¯æ˜¯å€‹å€¼å¾—é—œæ³¨çš„è©±é¡Œï¼\n\nç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ èƒ½å¦æ”¹å–„é€™äº›æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯ä»–å€‘çš„æ€è€ƒå’Œæƒ…ç·’ã€‚ç‚ºäº†æ‰¾åˆ°ç­”æ¡ˆï¼Œä»–å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æŒ‘é¸äº†ç›¸é—œçš„ç ”ç©¶ï¼Œä¸¦åˆ†æäº†369åæ‚£è€…çš„æ•¸æ“šã€‚é€™æ˜¯ç¬¬ä¸€å€‹å°ˆé–€é‡å°è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥ç–¾ç—…ä¸­æ‡‰ç”¨çš„ç³»çµ±æ€§å›é¡§ã€‚\n\nçµæœé¡¯ç¤ºï¼Œé›–ç„¶è˜¿è””ç¡«ç´ åœ¨æ”¹å–„ä¸€äº›ç—‡ç‹€æ–¹é¢çš„æ•ˆæœä¸å¤ªæ˜é¡¯ï¼Œä½†åœ¨12é€±çš„è§€å¯Ÿä¸­ï¼Œå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ã€‚è€Œä¸”ï¼Œé€™çµ„æ‚£è€…åœ¨ä¸€äº›ä»£è¬æŒ‡æ¨™ä¸Šï¼Œå¦‚è†½å›ºé†‡å’Œä¸‰é…¸ç”˜æ²¹è„‚ï¼Œä¹Ÿæœ‰é¡¯è‘—ä¸‹é™ï¼\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœï¼Œå¯èƒ½å°ç²¾ç¥å¥åº·æœ‰ç›Šã€‚  \n2. ç ”ç©¶ç™¼ç¾å®ƒå°è² æ€§ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ï¼Œä¸”å°ä»£è¬æŒ‡æ¨™æœ‰æ­£é¢å½±éŸ¿ã€‚  \n3. æ•¸æ“šæœ‰é™ï¼Œçµæœéœ€è¦è¬¹æ…è§£è®€ï¼Œä½†é€™æ˜¯ä¸€å€‹æœ‰è¶£çš„ç ”ç©¶æ–¹å‘ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experiment and main findings of a study on sulforaphane, a compound from broccoli. Use a flat design style with a white or light-colored background and soft colors. Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects (like people or cells), arrows or flow lines to indicate the experimental steps, and a section highlighting the main results (such as protective effects or changes in metabolic markers).",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "journal": "Placenta",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„æƒ…æ³ä¸‹ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®å¯èƒ½å°æ¯é«”å’Œèƒå…’é€ æˆå‚·å®³çš„ç–¾ç—…ï¼Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç–¾ç—…çš„å½±éŸ¿ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œèƒ½å¤ æ”¹å–„è¡€ç®¡åŠŸèƒ½ï¼Œé€™ä½¿å¾—å®ƒæˆç‚ºæœªä¾†æ²»ç™‚å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ½›åœ¨é¸æ“‡ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºå­•å©¦å’Œèƒå…’çš„å¥åº·æä¾›æ–°çš„ä¿è­·æªæ–½ï¼Œä¸¦å¼•ç™¼å°æ–¼å¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é€²è¡Œç–¾ç—…é é˜²çš„é€²ä¸€æ­¥æ€è€ƒã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»æƒ…æ³ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®ä»¥é«˜è¡€å£“å’Œæ¯é«”å™¨å®˜åŠŸèƒ½éšœç¤™ç‚ºç‰¹å¾µçš„ç–¾ç—…ï¼Œå°å­•å©¦å’Œèƒå…’çš„å¥åº·éƒ½æœ‰æ½›åœ¨å¨è„…ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”è©•ä¼°å…¶åœ¨å¦Šå¨ æœŸé–“çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "é€™é …ç ”ç©¶æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†äº†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä»¥åŠè‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2è‡³4å¤©ï¼Œç ”ç©¶è€…å†æ¬¡çµ¦äºˆå­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ã€‚æ‰€æœ‰æ¨£æœ¬éƒ½ç¶“éæ¶²ç›¸è‰²è­œè³ªè­œåˆ†æï¼Œä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å¤–å‘¨èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯é—œæ–¼è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰çš„æƒ…æ³ä¸‹ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®å¯èƒ½å°æ¯é«”å’Œèƒå…’é€ æˆå‚·å®³çš„ç–¾ç—…ï¼Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç–¾ç—…çš„å½±éŸ¿ã€‚ç”±æ–¼è˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œèƒ½å¤ æ”¹å–„è¡€ç®¡åŠŸèƒ½ï¼Œé€™ä½¿å¾—å®ƒæˆç‚ºæœªä¾†æ²»ç™‚å¦Šå¨ é«˜è¡€å£“ç—‡çš„æ½›åœ¨é¸æ“‡ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºå­•å©¦å’Œèƒå…’çš„å¥åº·æä¾›æ–°çš„ä¿è­·æªæ–½ï¼Œä¸¦å¼•ç™¼å°æ–¼å¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©é€²è¡Œç–¾ç—…é é˜²çš„é€²ä¸€æ­¥æ€è€ƒã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»æƒ…æ³ã€‚å¦Šå¨ é«˜è¡€å£“ç—‡æ˜¯ä¸€ç¨®ä»¥é«˜è¡€å£“å’Œæ¯é«”å™¨å®˜åŠŸèƒ½éšœç¤™ç‚ºç‰¹å¾µçš„ç–¾ç—…ï¼Œå°å­•å©¦å’Œèƒå…’çš„å¥åº·éƒ½æœ‰æ½›åœ¨å¨è„…ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼Œä¸¦ä¸”è©•ä¼°å…¶åœ¨å¦Šå¨ æœŸé–“çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚ï¼Œè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢ã€‚ç ”ç©¶è€…åœ¨æ‰‹è¡“å‰çµ¦äºˆé€™äº›å­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼ˆç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ï¼‰ï¼Œä¸¦åœ¨æ‰‹è¡“å‰å¾Œæ”¶é›†äº†å¥¹å€‘çš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä»¥åŠè‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚æ‰‹è¡“å¾Œ2è‡³4å¤©ï¼Œç ”ç©¶è€…å†æ¬¡çµ¦äºˆå­•å©¦ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ã€‚æ‰€æœ‰æ¨£æœ¬éƒ½ç¶“éæ¶²ç›¸è‰²è­œè³ªè­œåˆ†æï¼Œä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œå­•å©¦çš„å¤–å‘¨èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯é—œæ–¼è˜¿è””ç¡«ç´ å°èƒå…’å¥åº·çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPlacentaã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ‰ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°å­•å©¦çš„å¥åº·å¯èƒ½æœ‰å¾ˆå¤§çš„å¹«åŠ©å“¦ï¼ğŸ¤°âœ¨é€™æ¬¡çš„ç ”ç©¶å°ˆæ³¨æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½è®“åª½åª½å’Œå¯¶å¯¶éƒ½å—åˆ°å½±éŸ¿çš„ç–¾ç—…ã€‚ç ”ç©¶è€…å€‘æƒ³çœ‹çœ‹è˜¿è””ç¡«ç´ èƒ½ä¸èƒ½å¾åª½åª½çš„èº«é«”è½‰ç§»åˆ°å¯¶å¯¶èº«ä¸Šï¼Œä¸¦ä¸”äº†è§£å®ƒçš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚  \n  \nä»–å€‘æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œåœ¨å‰–è…¹ç”¢å‰çµ¦äºˆå¥¹å€‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦æ”¶é›†äº†è¨±å¤šæ¨£æœ¬ä¾†åˆ†æã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åœ¨åª½åª½çš„è¡€æ¶²ä¸­è¢«æª¢æ¸¬åˆ°ï¼Œé‚„æˆåŠŸè½‰ç§»åˆ°äº†è‡å¸¶è¡€å’Œæ¯ä¹³ä¸­ï¼é€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ é€²å…¥èƒå…’çš„è­‰æ“šã€‚é›–ç„¶æ‰‹è¡“ç•¶å¤©åª½åª½çš„è¡€å£“æœ‰äº›è®ŠåŒ–ï¼Œä½†æ•´é«”ä¸Šä¸¦æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚é€™äº›çµæœè®“æˆ‘å€‘å°æœªä¾†çš„ç ”ç©¶å……æ»¿æœŸå¾…ï¼  \n  \nğŸ”é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¦Šå¨ é«˜è¡€å£“ç—‡çš„é é˜²ã€‚  \n2. ç ”ç©¶é¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚  \n3. å°æ–¼å­•å©¦å’Œå¯¶å¯¶çš„å¥åº·ï¼Œé€™å¯èƒ½æ˜¯å€‹æ–°çš„ç ”ç©¶æ–¹å‘ï¼",
    "image_prompt": "Create an infographic illustrating the experiment and key findings of a study on the potential benefits of sulforaphane from radishes for pregnant women. Use a flat design style with a white or light-colored background and soft color palette. Include symbols of broccoli or radishes, simplified illustrations of human subjects, and arrows or flow lines to represent the experimental steps. Add a section highlighting the main results, such as the protective effects and transfer of sulforaphane to the fetus.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "journal": "Bioorganic & medicinal chemistry",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ²»ç™‚é€šå¸¸éœ€è¦é€²è¡Œå†çŒæ³¨ç™‚æ³•ï¼Œä½†é€™å¯èƒ½æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·çš„ç‰¹å¾µæ˜¯éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œèƒ½å¤ å•Ÿå‹•Nrf2é€šè·¯ï¼Œæ¸›å°‘ç·šç²’é«”ä¸­çš„ROSï¼Œé€™å°æ–¼æ¸›è¼•å¿ƒè¡€ç®¡ç–¾ç—…çš„æå‚·å¯èƒ½æœ‰å¹«åŠ©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¦‚ä½•é€šéæ”¹è‰¯é€™äº›åŒ–åˆç‰©çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œæ²»ç™‚æ•ˆæœï¼Œå¾è€Œæ¸›å°‘å¿ƒè‡Ÿç´°èƒåœ¨ç¼ºæ°§å†æ°§åˆéç¨‹ä¸­å—åˆ°çš„æå‚·ã€‚é€™ä¸€ç ”ç©¶ä¸åƒ…æ¶‰åŠåŒ–åˆç‰©çš„åˆæˆï¼Œé‚„åŒ…æ‹¬å…¶åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ•ˆæœè©•ä¼°ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦è©•ä¼°å…¶åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶ä½¿ç”¨äº†ç¼ºæ°§å†æ°§åˆæ¨¡å‹ä¾†æ¨¡æ“¬å¿ƒè‡Ÿæå‚·ï¼Œä¸¦æ¸¬é‡äº†ROSçš„æ°´å¹³ã€NOçš„ç”¢ç”Ÿä»¥åŠTNF-Î±çš„åˆ†æ³Œç­‰æŒ‡æ¨™ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦ï¼Œä¸¦åˆ©ç”¨åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†æ¢è¨é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§åŠå…¶å°Nrf2/Keap1é€šè·¯çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘ROSæ°´å¹³å’Œå¢åŠ NOç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”å…¶æŠ—å¢æ®–æ´»æ€§é¡¯è‘—é«˜æ–¼å‚³çµ±çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶ã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡ROSæ°´å¹³é™ä½24.5%ï¼Œä¸¦æé«˜NOç”¢ç”Ÿè‡³48.0Î¼Mï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒåŒ–åˆç‰©3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠç›¸é—œæ°§åŒ–å£“åŠ›çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ²»ç™‚é€šå¸¸éœ€è¦é€²è¡Œå†çŒæ³¨ç™‚æ³•ï¼Œä½†é€™å¯èƒ½æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·çš„ç‰¹å¾µæ˜¯éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å…·æœ‰æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œèƒ½å¤ å•Ÿå‹•Nrf2é€šè·¯ï¼Œæ¸›å°‘ç·šç²’é«”ä¸­çš„ROSï¼Œé€™å°æ–¼æ¸›è¼•å¿ƒè¡€ç®¡ç–¾ç—…çš„æå‚·å¯èƒ½æœ‰å¹«åŠ©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„ç¼ºè¡€å†çŒæ³¨æå‚·ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¦‚ä½•é€šéæ”¹è‰¯é€™äº›åŒ–åˆç‰©çš„çµæ§‹ä¾†æé«˜å…¶ç©©å®šæ€§å’Œæ²»ç™‚æ•ˆæœï¼Œå¾è€Œæ¸›å°‘å¿ƒè‡Ÿç´°èƒåœ¨ç¼ºæ°§å†æ°§åˆéç¨‹ä¸­å—åˆ°çš„æå‚·ã€‚é€™ä¸€ç ”ç©¶ä¸åƒ…æ¶‰åŠåŒ–åˆç‰©çš„åˆæˆï¼Œé‚„åŒ…æ‹¬å…¶åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ•ˆæœè©•ä¼°ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦è©•ä¼°å…¶åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„ä¿è­·æ•ˆæœã€‚ç ”ç©¶ä½¿ç”¨äº†ç¼ºæ°§å†æ°§åˆæ¨¡å‹ä¾†æ¨¡æ“¬å¿ƒè‡Ÿæå‚·ï¼Œä¸¦æ¸¬é‡äº†ROSçš„æ°´å¹³ã€NOçš„ç”¢ç”Ÿä»¥åŠTNF-Î±çš„åˆ†æ³Œç­‰æŒ‡æ¨™ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†ç©©å®šæ€§æ¸¬è©¦ï¼Œä¸¦åˆ©ç”¨åˆ†å­å°æ¥å’ŒADMETåˆ†æä¾†æ¢è¨é€™äº›åŒ–åˆç‰©çš„åˆ†å­ç‰¹æ€§åŠå…¶å°Nrf2/Keap1é€šè·¯çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©3gåœ¨æ¸›å°‘ROSæ°´å¹³å’Œå¢åŠ NOç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”å…¶æŠ—å¢æ®–æ´»æ€§é¡¯è‘—é«˜æ–¼å‚³çµ±çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶ã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡ROSæ°´å¹³é™ä½24.5%ï¼Œä¸¦æé«˜NOç”¢ç”Ÿè‡³48.0Î¼Mï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨å¿ƒè¡€ç®¡ç–¾ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒåŒ–åˆç‰©3gå¯èƒ½æˆç‚ºæ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·åŠç›¸é—œæ°§åŒ–å£“åŠ›çš„æœ‰å‰æ™¯çš„å€™é¸è—¥ç‰©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBioorganic & medicinal chemistryã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿåœ¨é¢å°æ€¥æ€§å¿ƒè‚Œæ¢—å¡çš„æ™‚å€™ï¼Œæœƒé­é‡åˆ°ä¸€ç¨®å«åšç¼ºè¡€å†çŒæ³¨æå‚·çš„å•é¡Œï¼Œé€™å¯ä¸å®¹å°è¦·ï¼æœ€è¿‘æœ‰ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œç™¼ç¾å®ƒå¯èƒ½å°å¿ƒè¡€ç®¡å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ã€‚é€™é …ç ”ç©¶çš„åœ˜éšŠåˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯åŒ–åˆç‰©3gï¼Œä¸¦åœ¨å¯¦é©—ä¸­æ¨¡æ“¬å¿ƒè‡Ÿæå‚·çš„æƒ…æ³ã€‚çµæœé¡¯ç¤ºï¼Œé€™äº›åŒ–åˆç‰©èƒ½æœ‰æ•ˆæ¸›å°‘å¿ƒè‡Ÿç´°èƒä¸­çš„æœ‰å®³ç‰©è³ªï¼ˆæ´»æ€§æ°§ï¼‰ä¸¦å¢åŠ ä¸€ç¨®å«åšä¸€æ°§åŒ–æ°®çš„æœ‰ç›Šç‰©è³ªçš„ç”¢ç”Ÿï¼Œé€™å°å¿ƒè‡Ÿçš„ä¿è­·éå¸¸é‡è¦ï¼é€™äº›ç™¼ç¾è®“äººå°æœªä¾†å¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚å……æ»¿æœŸå¾…ã€‚  \n\nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å¿ƒè‡Ÿæå‚·ã€‚  \n2. åŒ–åˆç‰©3gåœ¨æ¸›å°‘æœ‰å®³ç‰©è³ªå’Œå¢åŠ æœ‰ç›Šç‰©è³ªæ–¹é¢è¡¨ç¾çªå‡ºã€‚  \n3. é€™äº›çµæœç‚ºå¿ƒè¡€ç®¡ç–¾ç—…çš„æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experimental process and key results of a study on a compound called sulforaphane. Include simplified icons representing broccoli or sulforaphane, experimental subjects like cells or human figures, and arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Key Results' highlighting protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§å¿ƒè‚Œæ¢—å¡ Acute Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "journal": "Comparative biochemistry and physiology. Toxicology & pharmacology : CBP",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºèˆ‡è¨±å¤šç–¾ç—…çš„ç™¼å±•æœ‰é—œï¼ŒåŒ…æ‹¬è€åŒ–å’Œæ…¢æ€§ç—…ã€‚å› æ­¤ï¼Œäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„é é˜²ç­–ç•¥ï¼Œä¿ƒé€²å¥åº·ï¼Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·çš„äººä¾†èªªï¼Œå°¤å…¶é‡è¦ï¼Œå› ç‚ºè¨±å¤šå¤©ç„¶é£Ÿç‰©ä¸­éƒ½å«æœ‰é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œä¸¦å°ˆæ³¨æ–¼Nrf2çš„æ´»åŒ–ã€‚Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·ç´°èƒçš„åŸºå› ï¼Œä»¥å°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å®ƒå€‘åœ¨å¥åº·ä¿ƒé€²ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦å°‡å®ƒå€‘åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§å’ŒåŸºå› è¡¨é”ã€‚ç‚ºäº†é€²ä¸€æ­¥ç¢ºèªæŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„æ°´å¹³ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ï¼Œä¸¦è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„å¢å¼·äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°Nrf2çš„æ ¸å®šä½ï¼Œé€™è¡¨æ˜é€™äº›åŒ–åˆç‰©èƒ½ä¿ƒé€²Nrf2é€²å…¥ç´°èƒæ ¸ï¼Œé€²è€Œå•Ÿå‹•æŠ—æ°§åŒ–åæ‡‰ã€‚é€™äº›çµæœæš—ç¤ºesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦ä¸”å¯èƒ½é€éKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºèˆ‡è¨±å¤šç–¾ç—…çš„ç™¼å±•æœ‰é—œï¼ŒåŒ…æ‹¬è€åŒ–å’Œæ…¢æ€§ç—…ã€‚å› æ­¤ï¼Œäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„é é˜²ç­–ç•¥ï¼Œä¿ƒé€²å¥åº·ï¼Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·çš„äººä¾†èªªï¼Œå°¤å…¶é‡è¦ï¼Œå› ç‚ºè¨±å¤šå¤©ç„¶é£Ÿç‰©ä¸­éƒ½å«æœ‰é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œä¸¦å°ˆæ³¨æ–¼Nrf2çš„æ´»åŒ–ã€‚Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·ç´°èƒçš„åŸºå› ï¼Œä»¥å°æŠ—æ°§åŒ–æå‚·ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œäº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒçš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å®ƒå€‘åœ¨å¥åº·ä¿ƒé€²ä¸­çš„æ½›åœ¨æ‡‰ç”¨ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦å°‡å®ƒå€‘åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§å’ŒåŸºå› è¡¨é”ã€‚ç‚ºäº†é€²ä¸€æ­¥ç¢ºèªæŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„æ°´å¹³ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ï¼Œä¸¦è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„å¢å¼·äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­è§€å¯Ÿåˆ°Nrf2çš„æ ¸å®šä½ï¼Œé€™è¡¨æ˜é€™äº›åŒ–åˆç‰©èƒ½ä¿ƒé€²Nrf2é€²å…¥ç´°èƒæ ¸ï¼Œé€²è€Œå•Ÿå‹•æŠ—æ°§åŒ–åæ‡‰ã€‚é€™äº›çµæœæš—ç¤ºesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦ä¸”å¯èƒ½é€éKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Toxicology & pharmacology : CBPã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›é£Ÿç‰©è£¡çš„å¤©ç„¶æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼æ¯”è¼ƒå…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinï¼Œçœ‹çœ‹å®ƒå€‘å°æŠ—æ°§åŒ–çš„èƒ½åŠ›æœ‰å¤šå¼·ã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—èº«é«”å…§çš„è‡ªç”±åŸºï¼Œé€™äº›è‡ªç”±åŸºèˆ‡è€åŒ–å’Œæ…¢æ€§ç—…æœ‰é—œï¼Œäº†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„æ•ˆæœï¼Œæˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ä¿è­·å¥åº·ï¼\n\né€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†72å°æ™‚å¤§çš„æ–‘é¦¬é­šå¹¼é«”ï¼Œå°‡å®ƒå€‘åˆ†æˆå¹¾çµ„ï¼Œåˆ†åˆ¥çµ¦äºˆesculinå’Œè˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå®ƒå€‘çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚ä»–å€‘æ¸¬é‡äº†æ´»æ€§æ°§ã€è„‚è³ªéæ°§åŒ–å’ŒæŠ—æ°§åŒ–é…¶çš„æ´»æ€§ç­‰æŒ‡æ¨™ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æäº†ç›¸é—œåŸºå› çš„è¡¨ç¾ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œesculinçš„æŠ—æ°§åŒ–æ•ˆæœå’Œè˜¿è””ç¡«ç´ ç›¸ä¼¼ï¼Œé‚„èƒ½ä¿ƒé€²ä¸€äº›ä¿è­·åŸºå› çš„è¡¨é”ï¼Œé€™æ„å‘³è‘—å®ƒå€‘éƒ½èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–æå‚·ï¼\n\nğŸ” ç¸½çµä¾†èªªï¼š\n1. è˜¿è””ç¡«ç´ å’Œesculinéƒ½å…·æœ‰æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n2. é€™äº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ä¿ƒé€²ã€‚\n3. äº†è§£é€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„ä½œç”¨ï¼Œæœ‰åŠ©æ–¼æˆ‘å€‘é¸æ“‡æ›´å¥åº·çš„é£²é£Ÿï¼",
    "image_prompt": "Create a simple and informative infographic that explains the experimental methods and main results of a study comparing the antioxidant potential of two natural compounds: sulforaphane and esculin. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like fish or cells, arrows or flow lines showing the experimental steps, and a section highlighting 'Main Results' such as protective effects and changes observed. Use a flat design style with a white or light-colored background and soft colors.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "journal": "British journal of pharmacology",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å…·æœ‰é¡¯è‘—çš„å¥åº·ç›Šè™•ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚ç„¶è€Œï¼Œå‚³çµ±çš„è˜¿è””ç¡«ç´ åœ¨æº¶è§£åº¦å’Œå‚³éä¸Šå­˜åœ¨æŒ‘æˆ°ï¼Œé€™å¯èƒ½é™åˆ¶äº†å®ƒçš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éæ”¹è‰¯çš„å‚³éç³»çµ±ä¾†æå‡è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™¼ç‚æ€§ç–¾ç—…çš„æ²»ç™‚ï¼Œé€™å°æ–¼æ”¹å–„äººå€‘çš„å¥åº·ç‹€æ³å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -ç³–è‹·ï¼ˆSFN-glycoconjugatesï¼‰å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•å¢å¼·é€™äº›åŒ–åˆç‰©åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦å¸Œæœ›æ‰¾åˆ°ä¸€ç¨®æœ‰æ•ˆçš„æ–¹å¼ä¾†æ”¹å–„è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯ç”¨æ€§ï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨æ–¼è‡¨åºŠå’ŒåŠŸèƒ½æ€§é£Ÿå“ä¸­ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾å¥åº·çš„æè´ˆè€…ç²å–å–®æ ¸ç´°èƒï¼Œä¸¦å°‡å…¶è½‰åŒ–ç‚ºæ¨¹çªç´°èƒï¼ˆDCsï¼‰ã€‚é€™äº›æ¨¹çªç´°èƒåœ¨æ…¢æ€§LPSçš„åˆºæ¿€ä¸‹é€²è¡Œè™•ç†ï¼Œç„¶å¾Œæ¥å—è˜¿è””ç¡«ç´ -ç³–è‹·çš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘æ¸¬è©¦äº†é€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ–¹é¢çš„æ•ˆæœï¼Œä¸¦è§€å¯Ÿå…¶å°ç´°èƒä¿¡è™Ÿå‚³éè·¯å¾‘çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·èƒ½é¡¯è‘—æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©å¯ç”¨æ€§ï¼Œä¸¦åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBè·¯å¾‘ä¾†é”æˆé€™ä¸€æ•ˆæœï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©èƒ½èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨ç™¼ç‚æ€§ç–¾ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å…·æœ‰é¡¯è‘—çš„å¥åº·ç›Šè™•ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚ç„¶è€Œï¼Œå‚³çµ±çš„è˜¿è””ç¡«ç´ åœ¨æº¶è§£åº¦å’Œå‚³éä¸Šå­˜åœ¨æŒ‘æˆ°ï¼Œé€™å¯èƒ½é™åˆ¶äº†å®ƒçš„ç™‚æ•ˆã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éæ”¹è‰¯çš„å‚³éç³»çµ±ä¾†æå‡è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°ç™¼ç‚æ€§ç–¾ç—…çš„æ²»ç™‚ï¼Œé€™å°æ–¼æ”¹å–„äººå€‘çš„å¥åº·ç‹€æ³å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ -ç³–è‹·ï¼ˆSFN-glycoconjugatesï¼‰å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•å¢å¼·é€™äº›åŒ–åˆç‰©åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦å¸Œæœ›æ‰¾åˆ°ä¸€ç¨®æœ‰æ•ˆçš„æ–¹å¼ä¾†æ”¹å–„è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯ç”¨æ€§ï¼Œä»¥ä¾¿æ›´å¥½åœ°æ‡‰ç”¨æ–¼è‡¨åºŠå’ŒåŠŸèƒ½æ€§é£Ÿå“ä¸­ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾å¥åº·çš„æè´ˆè€…ç²å–å–®æ ¸ç´°èƒï¼Œä¸¦å°‡å…¶è½‰åŒ–ç‚ºæ¨¹çªç´°èƒï¼ˆDCsï¼‰ã€‚é€™äº›æ¨¹çªç´°èƒåœ¨æ…¢æ€§LPSçš„åˆºæ¿€ä¸‹é€²è¡Œè™•ç†ï¼Œç„¶å¾Œæ¥å—è˜¿è””ç¡«ç´ -ç³–è‹·çš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘æ¸¬è©¦äº†é€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€æ–¹é¢çš„æ•ˆæœï¼Œä¸¦è§€å¯Ÿå…¶å°ç´°èƒä¿¡è™Ÿå‚³éè·¯å¾‘çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·èƒ½é¡¯è‘—æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©å¯ç”¨æ€§ï¼Œä¸¦åœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œç‰¹åˆ¥æ˜¯é€šéé‡å°p65 NF-ÎºBè·¯å¾‘ä¾†é”æˆé€™ä¸€æ•ˆæœï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©èƒ½èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨ç™¼ç‚æ€§ç–¾ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“è˜¿è””ç¡«ç´ ä¸åƒ…èƒ½è®“ä½ çš„è”¬èœæ›´ç¾å‘³ï¼Œé‚„å¯èƒ½å°å¥åº·æœ‰å¤§å¹«åŠ©å—ï¼Ÿæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ åœ¨æŠ—ç™¼ç‚æ–¹é¢çš„æ½›åŠ›éå¸¸å€¼å¾—æ³¨æ„ï¼ä¸éï¼Œå‚³çµ±çš„è˜¿è””ç¡«ç´ åœ¨èº«é«”è£¡çš„æº¶è§£åº¦å’Œå¸æ”¶ç‡æœ‰é»æŒ‘æˆ°ï¼Œé€™è®“å®ƒçš„æ•ˆæœå—é™ã€‚ \n\né€™é …ç ”ç©¶çš„åœ˜éšŠå°ˆæ³¨æ–¼ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ -ç³–è‹·ï¼Œæƒ³çœ‹çœ‹å®ƒèƒ½å¦åœ¨æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ä¸Šæ›´æœ‰æ•ˆã€‚ä»–å€‘å¾å¥åº·çš„æè´ˆè€…é‚£è£¡ç²å¾—äº†ç´°èƒï¼Œç„¶å¾Œç”¨é€™äº›ç´°èƒé€²è¡Œå¯¦é©—ï¼Œçœ‹çœ‹é€™ç¨®æ–°åŒ–åˆç‰©çš„æ•ˆæœã€‚ \n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·ä¸åƒ…èƒ½æé«˜æº¶è§£åº¦ï¼Œé‚„èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯é€šéä¸€å€‹å«åšNF-ÎºBçš„è·¯å¾‘ä¾†é”æˆï¼Œä¸¦ä¸”é‚„èƒ½ä¿ƒé€²ä¸€äº›å…ç–«ç´°èƒçš„å¢ç”Ÿï¼Œé€™å°æ–¼æ²»ç™‚ç™¼ç‚æ€§ç–¾ç—…ä¾†èªªæ˜¯å€‹å¥½æ¶ˆæ¯ï¼\n\nâœ¨ ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ -ç³–è‹·èƒ½æ”¹å–„æº¶è§£åº¦å’Œå¸æ”¶ç‡ã€‚\n2. å®ƒåœ¨æŠ‘åˆ¶ç™¼ç‚æ–¹é¢æ•ˆæœé¡¯è‘—ã€‚\n3. æœ‰æ½›åŠ›åœ¨ç™¼ç‚æ€§ç–¾ç—…çš„æ²»ç™‚ä¸­ç™¼æ®ä½œç”¨ï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on sulforaphane-glycosides. Include simplified icons representing broccoli or sulforaphane, experimental subjects like human or cell illustrations, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚æ€§ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "journal": "Mikrochimica acta",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼Œä¸¦ä¿ƒé€²æˆ‘å€‘å°æ¤ç‰©ä¾†æºçš„è—¥ç‰©çš„èªè­˜ï¼Œé€²è€Œå¯èƒ½æ”¹å–„å¥åº·ç‹€æ³æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œå› ç‚ºå®ƒå€‘ä¸»è¦å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©ä¸­ï¼Œé€™é™åˆ¶äº†å…¶åœ¨å…¶ä»–æ¤ç‰©ä¸­çš„æ‡‰ç”¨ã€‚é€éé–‹ç™¼æ–°çš„æª¢æ¸¬æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ“´å¤§é€™äº›æœ‰ç›ŠåŒ–åˆç‰©çš„ä¾†æºï¼Œä¸¦ä¿ƒé€²å…¶åœ¨é†«å­¸ä¸Šçš„æ‡‰ç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–ï¼ˆonline SPEï¼‰çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°è‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé¡¯ç¤ºé€™ç¨®æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œç ”ç©¶è€…åœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡ç¯„åœç‚º89.1%åˆ°109.3%ï¼Œç›¸å°æ¨™æº–åå·®ï¼ˆRSDï¼‰å°æ–¼ç­‰æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆUPLC-MS/MSçš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥æ›´æ·±å…¥äº†è§£å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–é€™äº›æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼Œä¸¦ä¿ƒé€²æˆ‘å€‘å°æ¤ç‰©ä¾†æºçš„è—¥ç‰©çš„èªè­˜ï¼Œé€²è€Œå¯èƒ½æ”¹å–„å¥åº·ç‹€æ³æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æœ‰æ•ˆåœ°æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œå› ç‚ºå®ƒå€‘ä¸»è¦å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘æ¤ç‰©ä¸­ï¼Œé€™é™åˆ¶äº†å…¶åœ¨å…¶ä»–æ¤ç‰©ä¸­çš„æ‡‰ç”¨ã€‚é€éé–‹ç™¼æ–°çš„æª¢æ¸¬æ–¹æ³•ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ“´å¤§é€™äº›æœ‰ç›ŠåŒ–åˆç‰©çš„ä¾†æºï¼Œä¸¦ä¿ƒé€²å…¶åœ¨é†«å­¸ä¸Šçš„æ‡‰ç”¨ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–ï¼ˆonline SPEï¼‰çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œç ”ç©¶è€…è§€å¯Ÿåˆ°è‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé¡¯ç¤ºé€™ç¨®æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œç ”ç©¶è€…åœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡ç¯„åœç‚º89.1%åˆ°109.3%ï¼Œç›¸å°æ¨™æº–åå·®ï¼ˆRSDï¼‰å°æ–¼ç­‰æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆUPLC-MS/MSçš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "æ ¹æ“šã€ŠMikrochimica actaã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘èº«é‚Šçš„éå¯é£Ÿç”¨æ¤ç‰©ä¹Ÿå¯èƒ½è—è‘—å¥åº·çš„ç§˜å¯†ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œé€™æ±è¥¿åœ¨é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­æœ‰ç™¼ç¾ï¼Œæ“šèªªå°å¥åº·æœ‰ä¸å°‘å¥½è™•ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œå¦‚ä½•å¾é€™äº›éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–è˜¿è””ç¡«ç´ åŠå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ï¼Œä¸¦æª¢æ¸¬å®ƒå€‘çš„å­˜åœ¨ã€‚  \n\nä»–å€‘é–‹ç™¼äº†ä¸€ç¨®æ–°çš„æª¢æ¸¬æ–¹æ³•ï¼Œä½¿ç”¨äº†ä¸€ç¨®å«åšæ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶çš„ææ–™ä¾†æ•æ‰é€™äº›åŒ–åˆç‰©ã€‚åœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘æª¢æ¸¬äº†18ç¨®éå¯é£Ÿç”¨æ¤ç‰©ï¼Œçµæœç™¼ç¾é€™äº›æ¤ç‰©ä¸­ä¹Ÿèƒ½æ‰¾åˆ°è˜¿è””ç¡«ç´ å’Œè‘¡è„ç³–è˜¿è””ç¡«ç´ ï¼Œå›æ”¶ç‡ç›¸ç•¶é«˜ï¼Œé¡¯ç¤ºå‡ºé€™ç¨®æª¢æ¸¬æ–¹æ³•çš„æ½›åŠ›ï¼  \n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œå°¤å…¶æ˜¯å¾éå¯é£Ÿç”¨æ¤ç‰©ä¸­æå–ã€‚  \n2. æ–°çš„æª¢æ¸¬æ–¹æ³•é¡¯ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœï¼Œèƒ½æ“´å¤§æˆ‘å€‘çš„æ¤ç‰©ä¾†æºã€‚  \n3. é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create an informative illustration showing the experiment process and main results of the study on sulforaphane extraction from non-edible plants. The image should have a flat design style with a white or light-colored background and soft color palette. Include symbols or icons representing broccoli or sulforaphane, simplified representations of experimental subjects like humans or cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as recovery rates and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "journal": "Frontiers in immunology",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„ä½œç”¨ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æ–°çš„è¦–è§’ï¼Œå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…æ–¹é¢çš„å¤šé‡æ©Ÿåˆ¶ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿äººé«”å…§çš„ä¸åŒç”Ÿç‰©éç¨‹ï¼Œæˆ‘å€‘å¯ä»¥æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶ç‰©è³ªä¾†å¢å¼·æˆ‘å€‘çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é˜²æ²»çš„é ˜åŸŸã€‚é€™ä¹Ÿæ„å‘³è‘—ï¼Œé€éç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µï¼Œæˆ‘å€‘å¯ä»¥æ ¹æ“šå€‹äººçš„ç”Ÿç†ç‰¹å¾µä¾†èª¿æ•´é£²é£Ÿï¼Œä»¥é”åˆ°æœ€ä½³çš„å¥åº·æ•ˆæœã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒï¼Œä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€éæ•´åˆä¸åŒç ”ç©¶é ˜åŸŸçš„è³‡æ–™ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æä¾›ä¸€å€‹æ›´å…¨é¢çš„ç†è§£ï¼Œè®“æˆ‘å€‘çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨åˆ†å­å±¤é¢ä¸Šå½±éŸ¿ç™Œç—‡çš„ç™¼å±•å’Œæ²»ç™‚ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œç„¶å¾Œå†åˆ°å…¶åœ¨äººé«”å…§çš„ä½œç”¨ã€‚ç ”ç©¶è€…é‚„è€ƒé‡äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡ç ”ç©¶æ–¹æ³•ä½¿å¾—ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ï¼Œä¸¦èƒ½å¤ ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æŒ‡å°ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…å¼·èª¿ï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”æ©Ÿåˆ¶ä¸åƒ…åƒ…æ˜¯ä¸€èˆ¬çš„å”åŒä½œç”¨ï¼Œè€Œæ˜¯èƒ½å¤ åœ¨åˆ†å­å±¤é¢ä¸Šå½±éŸ¿ç™Œç—‡çš„æ²»ç™‚æ•ˆæœã€‚é€™äº›çµæœç‚ºæˆ‘å€‘æä¾›äº†æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°ç†è§£å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ”¹å–„ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æ•ˆæœï¼Œä¸¦æ¨å‹•ç²¾æº–é†«ç™‚çš„ç™¼å±•ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„ä½œç”¨ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æ–°çš„è¦–è§’ï¼Œå¼·èª¿äº†è˜¿è””ç¡«ç´ åœ¨ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…æ–¹é¢çš„å¤šé‡æ©Ÿåˆ¶ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿äººé«”å…§çš„ä¸åŒç”Ÿç‰©éç¨‹ï¼Œæˆ‘å€‘å¯ä»¥æ›´å¥½åœ°åˆ©ç”¨é€™ç¨®å¤©ç„¶ç‰©è³ªä¾†å¢å¼·æˆ‘å€‘çš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é˜²æ²»çš„é ˜åŸŸã€‚é€™ä¹Ÿæ„å‘³è‘—ï¼Œé€éç²¾æº–ç‡Ÿé¤Šçš„æ¦‚å¿µï¼Œæˆ‘å€‘å¯ä»¥æ ¹æ“šå€‹äººçš„ç”Ÿç†ç‰¹å¾µä¾†èª¿æ•´é£²é£Ÿï¼Œä»¥é”åˆ°æœ€ä½³çš„å¥åº·æ•ˆæœã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒï¼Œä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€éæ•´åˆä¸åŒç ”ç©¶é ˜åŸŸçš„è³‡æ–™ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æä¾›ä¸€å€‹æ›´å…¨é¢çš„ç†è§£ï¼Œè®“æˆ‘å€‘çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨åˆ†å­å±¤é¢ä¸Šå½±éŸ¿ç™Œç—‡çš„ç™¼å±•å’Œæ²»ç™‚ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ¡ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œç„¶å¾Œå†åˆ°å…¶åœ¨äººé«”å…§çš„ä½œç”¨ã€‚ç ”ç©¶è€…é‚„è€ƒé‡äº†å®¿ä¸»å› ç´ ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œè°·èƒ±ç”˜è‚½S-è½‰ç§»é…¶çš„å¤šæ…‹æ€§ï¼Œé€™äº›å› ç´ æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€™æ¨£çš„å¤šå±¤æ¬¡ç ”ç©¶æ–¹æ³•ä½¿å¾—ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ï¼Œä¸¦èƒ½å¤ ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›æŒ‡å°ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨å¢å¼·å‚³çµ±æ²»ç™‚æ–¹é¢å…·æœ‰æ½›åŠ›ï¼Œå°¤å…¶æ˜¯åœ¨èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»æ–¹é¢ã€‚ç ”ç©¶è€…å¼·èª¿ï¼Œè˜¿è””ç¡«ç´ çš„å…·é«”æ©Ÿåˆ¶ä¸åƒ…åƒ…æ˜¯ä¸€èˆ¬çš„å”åŒä½œç”¨ï¼Œè€Œæ˜¯èƒ½å¤ åœ¨åˆ†å­å±¤é¢ä¸Šå½±éŸ¿ç™Œç—‡çš„æ²»ç™‚æ•ˆæœã€‚é€™äº›çµæœç‚ºæˆ‘å€‘æä¾›äº†æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°ç†è§£å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ”¹å–„ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æ•ˆæœï¼Œä¸¦æ¨å‹•ç²¾æº–é†«ç™‚çš„ç™¼å±•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in immunologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹å°å°çš„åŒ–åˆç‰©ï¼Œå¯èƒ½åœ¨ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ä¸Šç™¼æ®å¤§ä½œç”¨ï¼é€™æ˜¯ä¸€é …æ–°ç ”ç©¶çš„ç™¼ç¾ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹å§ï¼\n\nç ”ç©¶è€…å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ åˆ°åº•æ€éº¼å½±éŸ¿ç™Œç—‡ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒå’Œè…«ç˜¤çš„å…ç–«ç’°å¢ƒã€‚ä»–å€‘ä½¿ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆï¼Œç„¶å¾Œçœ‹çœ‹å®ƒåœ¨æˆ‘å€‘èº«é«”è£¡çš„ä½œç”¨ã€‚é‚„è€ƒæ…®äº†è…¸é“å¾®ç”Ÿç‰©çš„å½±éŸ¿ï¼Œé€™äº›éƒ½æœƒå½±éŸ¿è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\næœ€æœ‰è¶£çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½å¢å¼·å‚³çµ±æ²»ç™‚ï¼Œé‚„èƒ½åœ¨åˆ†å­å±¤é¢ä¸Šèª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»ã€‚é€™è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚æœ‰äº†æ–°çš„æ€è·¯ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚\n2. ç ”ç©¶è€ƒé‡äº†å¤šç¨®å½±éŸ¿å› ç´ ï¼Œè®“çµæœæ›´å¯é ã€‚\n3. è˜¿è””ç¡«ç´ åœ¨æå‡æ²»ç™‚æ•ˆæœä¸Šæœ‰æ½›åŠ›ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on sulforaphane. Use a flat design style with a white or light background and soft colors. Include simplified icons representing broccoli or sulforaphane, simplified figures of experimental subjects (like humans, animals, or cells), arrows or flow lines to indicate the steps of the experiment, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "journal": "Biochemical and biophysical research communications",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½å°èƒƒç™Œçš„é é˜²å’Œæ²»ç™‚æœ‰æ‰€å¹«åŠ©ï¼Œé›–ç„¶é€™ä»éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œç‰¹å®šçš„lncRNAåœ¨èƒƒç™Œä¸­çš„è¡¨ç¾å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¢æ®–å’Œè½‰ç§»ï¼Œä¸¦ä¸”è˜¿è””ç¡«ç´ åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†ä»€éº¼æ¨£çš„è§’è‰²ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œä¸¦æ‰¾åˆ°äº†é¡¯è‘—è¡¨é”å·®ç•°çš„lncRNA PSMB8AS1ã€‚æ¥è‘—ï¼Œä»–å€‘åˆ©ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œäº†é€²ä¸€æ­¥çš„åˆ†æï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡ç›¸é—œã€‚ç ”ç©¶é‚„ä½¿ç”¨äº†å¤šç¨®å¯¦é©—æ–¹æ³•ä¾†æ¢è¨PSMB8-AS1çš„åŠŸèƒ½ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡çš„æ¸¬è©¦ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾PSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿ç¯€SLC4A7çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé›–ç„¶é€™äº›çµæœä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠé©—è­‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½å°èƒƒç™Œçš„é é˜²å’Œæ²»ç™‚æœ‰æ‰€å¹«åŠ©ï¼Œé›–ç„¶é€™ä»éœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œç‰¹å®šçš„lncRNAåœ¨èƒƒç™Œä¸­çš„è¡¨ç¾å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¢æ®–å’Œè½‰ç§»ï¼Œä¸¦ä¸”è˜¿è””ç¡«ç´ åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”äº†ä»€éº¼æ¨£çš„è§’è‰²ã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œä¸¦æ‰¾åˆ°äº†é¡¯è‘—è¡¨é”å·®ç•°çš„lncRNA PSMB8AS1ã€‚æ¥è‘—ï¼Œä»–å€‘åˆ©ç”¨TCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œäº†é€²ä¸€æ­¥çš„åˆ†æï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡ç›¸é—œã€‚ç ”ç©¶é‚„ä½¿ç”¨äº†å¤šç¨®å¯¦é©—æ–¹æ³•ä¾†æ¢è¨PSMB8-AS1çš„åŠŸèƒ½ï¼ŒåŒ…æ‹¬ç´°èƒå¢æ®–ã€é·ç§»å’Œå‡‹äº¡çš„æ¸¬è©¦ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾PSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿ç¯€SLC4A7çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé›–ç„¶é€™äº›çµæœä»éœ€é€²ä¸€æ­¥çš„è‡¨åºŠé©—è­‰ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiochemical and biophysical research communicationsã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ åƒé’èŠ±æ¤°èœçœŸçš„æœ‰åŠ©æ–¼å¥åº·å—ï¼Ÿæœ€è¿‘ä¸€é …ç ”ç©¶æ­ç¤ºäº†è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œé˜²æ²»æ–¹é¢ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€ç´°èƒä¸­çš„æŸäº›åˆ†å­ä¾†æŠ‘åˆ¶èƒƒç™Œçš„å½¢æˆã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œç‰¹å®šçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨ç¾èˆ‡ç™Œç´°èƒçš„å¢æ®–å’Œè½‰ç§»æœ‰é—œï¼Œè€Œè˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­ä¼¼ä¹æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚\n\nç§‘å­¸å®¶å€‘å°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œäº†åˆ†æï¼Œç™¼ç¾ä¸€ç¨®å«PSMB8-AS1çš„lncRNAåœ¨ç™Œç´°èƒä¸­è¡¨é”ä¸Šå‡ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚é€²ä¸€æ­¥çš„å¯¦é©—é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„è¡¨é”èƒ½é¡¯è‘—æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚\n\nğŸ¤” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼èƒƒç™Œçš„é é˜²å’Œæ²»ç™‚ã€‚\n2. PSMB8-AS1èˆ‡èƒƒç™Œçš„å¢æ®–å’Œè½‰ç§»æœ‰é—œã€‚\n3. æŠ‘åˆ¶PSMB8-AS1å¯æ¸›å°‘ç™Œç´°èƒçš„ç”Ÿé•·ã€‚\n\né›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœå–”ï¼",
    "image_prompt": "Create an informative infographic that explains the experimental methods and main results of a study on the effects of sulforaphane on stomach cancer. The design should feature a simple illustration of broccoli or a symbol representing sulforaphane. Include simplified representations of experimental subjects like cells or humans. Use arrows or flow lines to indicate the steps of the experiment. Dedicate a section to highlight the main results, such as protective effects or changes observed. The style should be flat design with a white or light-colored background and soft color palette.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "journal": "RSC medicinal chemistry",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ï¼Œç ”ç©¶è€…å€‘æ­£åœ¨å°‹æ‰¾æ–°çš„æ–¹æ³•ä¾†é–‹ç™¼æ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ã€‚é€éçµåˆè‡ªç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œé€™é …ç ”ç©¶å±•ç¤ºäº†å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†å‰µé€ å‡ºæ–°çš„è—¥ç‰©ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é›£æ²»çš„ç™Œç—‡é¡å‹æ™‚ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æŠ—ç™Œè—¥ç‰©çš„é–‹ç™¼ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œï¼ˆnasopharyngeal carcinoma, NPCï¼‰çš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ä¾†è¨­è¨ˆå‡ºæ–°çš„åˆ†å­æ··åˆç‰©ï¼Œé€™äº›æ··åˆç‰©èƒ½å¤ æœ‰æ•ˆåœ°å°æŠ—ç™Œç´°èƒï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°æ¯”ç¾æœ‰è—¥ç‰©æ›´å…·æ•ˆåŠ›çš„é¸æ“‡ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—çš„åˆ†å­æ··åˆç‰©ï¼Œé€™äº›æ··åˆç‰©æ˜¯ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©magnololçµåˆè€Œæˆã€‚ç ”ç©¶åœ˜éšŠå°é€™äº›æ–°åˆæˆçš„åŒ–åˆç‰©é€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§è©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹é€²è¡Œæ¸¬è©¦ï¼Œä»¥äº†è§£å®ƒå€‘çš„æ•ˆæœå’Œæ©Ÿåˆ¶ã€‚é€™äº›å¯¦é©—åŒ…æ‹¬äº†ç´°èƒçš„ç”Ÿé•·æŠ‘åˆ¶æ¸¬è©¦å’Œæ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥ç¢ºå®šé€™äº›åŒ–åˆç‰©çš„æŠ—ç™Œæ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™å€‹æ–°åŒ–åˆç‰©é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶çˆ¶åŒ–åˆç‰©å’Œé †é‰‘ï¼ˆcisplatinï¼‰ã€‚åœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­ï¼ŒCTNPC8èƒ½å¤ æœ‰æ•ˆèª˜å°ç´°èƒå‡‹äº¡ï¼Œä¸¦ä¸”é€šéèª¿ç¯€æ´»æ€§æ°§ï¼ˆROSï¼‰çš„ç”Ÿæˆä¾†å½±éŸ¿ç´°èƒé€±æœŸã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿æ§Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—é¼»å’½ç™ŒåŒ–åˆç‰©ï¼Œç‚ºæœªä¾†çš„æŠ—è…«ç˜¤è—¥ç‰©é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„æ–¹å‘ï¼Œå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯é‡å°ç™Œç—‡çš„æ²»ç™‚ï¼Œç ”ç©¶è€…å€‘æ­£åœ¨å°‹æ‰¾æ–°çš„æ–¹æ³•ä¾†é–‹ç™¼æ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ã€‚é€éçµåˆè‡ªç„¶ç”¢ç‰©çš„ç‰¹æ€§ï¼Œé€™é …ç ”ç©¶å±•ç¤ºäº†å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†å‰µé€ å‡ºæ–°çš„è—¥ç‰©ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„é¸æ“‡ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é›£æ²»çš„ç™Œç—‡é¡å‹æ™‚ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°æŠ—ç™Œè—¥ç‰©çš„é–‹ç™¼ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œï¼ˆnasopharyngeal carcinoma, NPCï¼‰çš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç”¢ç‰©çš„ç‰¹æ€§ä¾†è¨­è¨ˆå‡ºæ–°çš„åˆ†å­æ··åˆç‰©ï¼Œé€™äº›æ··åˆç‰©èƒ½å¤ æœ‰æ•ˆåœ°å°æŠ—ç™Œç´°èƒï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°æ¯”ç¾æœ‰è—¥ç‰©æ›´å…·æ•ˆåŠ›çš„é¸æ“‡ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—çš„åˆ†å­æ··åˆç‰©ï¼Œé€™äº›æ··åˆç‰©æ˜¯ç”±è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©magnololçµåˆè€Œæˆã€‚ç ”ç©¶åœ˜éšŠå°é€™äº›æ–°åˆæˆçš„åŒ–åˆç‰©é€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§è©•ä¼°ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹é€²è¡Œæ¸¬è©¦ï¼Œä»¥äº†è§£å®ƒå€‘çš„æ•ˆæœå’Œæ©Ÿåˆ¶ã€‚é€™äº›å¯¦é©—åŒ…æ‹¬äº†ç´°èƒçš„ç”Ÿé•·æŠ‘åˆ¶æ¸¬è©¦å’Œæ©Ÿåˆ¶ç ”ç©¶ï¼Œä»¥ç¢ºå®šé€™äº›åŒ–åˆç‰©çš„æŠ—ç™Œæ½›åŠ›ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒCTNPC8é€™å€‹æ–°åŒ–åˆç‰©é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶çˆ¶åŒ–åˆç‰©å’Œé †é‰‘ï¼ˆcisplatinï¼‰ã€‚åœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­ï¼ŒCTNPC8èƒ½å¤ æœ‰æ•ˆèª˜å°ç´°èƒå‡‹äº¡ï¼Œä¸¦ä¸”é€šéèª¿ç¯€æ´»æ€§æ°§ï¼ˆROSï¼‰çš„ç”Ÿæˆä¾†å½±éŸ¿ç´°èƒé€±æœŸã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿æ§Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœé¡¯ç¤ºCTNPC8æ˜¯ä¸€å€‹æœ‰æ½›åŠ›çš„æŠ—é¼»å’½ç™ŒåŒ–åˆç‰©ï¼Œç‚ºæœªä¾†çš„æŠ—è…«ç˜¤è—¥ç‰©é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠRSC medicinal chemistryã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½å°å¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½åˆ©ç”¨å®ƒä¾†é–‹ç™¼æ–°çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œã€‚ é€™é …ç ”ç©¶çš„é‡é»æ˜¯å¦‚ä½•å°‡è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®åŒ–åˆç‰©çµåˆï¼Œè¨­è¨ˆå‡ºèƒ½æœ‰æ•ˆå°æŠ—ç™Œç´°èƒçš„æ–°åˆ†å­ã€‚ç ”ç©¶åœ˜éšŠé€²è¡Œäº†å¤šé …å¯¦é©—ï¼Œæ¸¬è©¦é€™äº›æ–°åˆæˆçš„åŒ–åˆç‰©åœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­çš„æ•ˆæœã€‚ çµæœé¡¯ç¤ºï¼Œé€™å€‹æ–°åŒ–åˆç‰©CTNPC8çš„æŠ—ç™Œæ´»æ€§éå¸¸å¼·ï¼Œç”šè‡³æ¯”ç›®å‰å¸¸ç”¨çš„è—¥ç‰©é‚„è¦å¥½ï¼å®ƒèƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒå‡‹äº¡ï¼Œä¸¦é€éèª¿æ§ç´°èƒå…§çš„ä¸€äº›ä¿¡è™Ÿé€šè·¯ä¾†ç™¼æ®ä½œç”¨ã€‚ é€™é …ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°äº†æœªä¾†æŠ—ç™Œè—¥ç‰©é–‹ç™¼çš„æ–°æ–¹å‘ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰æ½›åŠ›æˆç‚ºæŠ—ç™Œè—¥ç‰©çš„åŸºç¤ã€‚\n2. CTNPC8åœ¨é¼»å’½ç™Œç´°èƒä¸­é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ•ˆæœã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æŠ—è…«ç˜¤è—¥ç‰©é–‹ç™¼æä¾›äº†æ–°æ€è·¯ã€‚",
    "image_prompt": "Create a simple and informative infographic that explains the experimental methods and main results of a study on a compound called CTNPC8 derived from sulforaphane. The design should include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting the compound's protective effects and mechanisms. Use a flat design style with a white or light-colored background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚ç ”ç©¶è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒæˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„æ²»ç™‚é¸æ“‡ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¸Œæœ›èƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·ä¸­çš„ä½œç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•ç”±LPSå¼•èµ·çš„è‚æå‚·ï¼Œä¸¦ä¸”å®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡å°è‡´çš„è‚æå‚·æ–¹é¢ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶äººå“¡å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚é€éçµ„ç¹”å­¸æŸ“è‰²å’ŒåŸºå› æ¸¬åºï¼Œç ”ç©¶è€…è©•ä¼°äº†è‚è‡Ÿçš„æå‚·ç¨‹åº¦åŠç‚ç—‡åæ‡‰ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶å°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶LPSå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦ä¸‹èª¿å¤šç¨®ç‚ç—‡ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSå¼•èµ·çš„è‚æå‚·å’Œç‚ç—‡ã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚ç ”ç©¶è¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒæˆç‚ºä¸€å€‹æœ‰æ½›åŠ›çš„æ²»ç™‚é¸æ“‡ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¸Œæœ›èƒ½å¤ æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·ä¸­çš„ä½œç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›ç§‘å­¸ä¾æ“šã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·ä¸­çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•ç”±LPSå¼•èµ·çš„è‚æå‚·ï¼Œä¸¦ä¸”å®ƒçš„ä½œç”¨æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚é€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡å°è‡´çš„è‚æå‚·æ–¹é¢ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ç ”ç©¶äººå“¡å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚é€éçµ„ç¹”å­¸æŸ“è‰²å’ŒåŸºå› æ¸¬åºï¼Œç ”ç©¶è€…è©•ä¼°äº†è‚è‡Ÿçš„æå‚·ç¨‹åº¦åŠç‚ç—‡åæ‡‰ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSå¼•èµ·çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶å°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶LPSå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦ä¸‹èª¿å¤šç¨®ç‚ç—‡ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSå¼•èµ·çš„è‚æå‚·å’Œç‚ç—‡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è‚è‡Ÿå°±åƒèº«é«”çš„æ¸…é“å¤«ï¼Œè² è²¬è§£æ¯’å’Œä»£è¬ï¼Œä½†æœ‰æ™‚å€™å®ƒä¹Ÿæœƒå—åˆ°å‚·å®³ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡é€™ç¨®æƒ…æ³ä¸‹ã€‚æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ€¥æ€§è‚æå‚·æœ‰ä¿è­·ä½œç”¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ èƒ½å¦å¹«åŠ©æ¸›è¼•ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„è‚æå‚·ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨å°é¼ é€²è¡Œå¯¦é©—ï¼Œå°‡å®ƒå€‘åˆ†æˆä¸‰çµ„ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚å¯¦é©—å¾Œï¼Œä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½è‚è‡Ÿæå‚·å’Œç‚ç—‡åæ‡‰ï¼Œé€™å°æœªä¾†çš„æ²»ç™‚ç­–ç•¥æœ‰é‡è¦æ„ç¾©ï¼\n\nç°¡å–®ä¾†èªªï¼Œé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•è‚æå‚·ã€‚\n2. å®ƒèƒ½æŠ‘åˆ¶ç‚ç—‡åæ‡‰ï¼Œä¿è­·è‚è‡Ÿã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†æ²»ç™‚ç›¸é—œç–¾ç—…æä¾›äº†æ–°çš„æ€è·¯ï¼\n\né›–ç„¶é€™äº›çµæœå¾ˆä»¤äººæŒ¯å¥®ï¼Œä½†æˆ‘å€‘ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªè˜¿è””ç¡«ç´ çš„æ•ˆæœå–”ï¼",
    "image_prompt": "Create a flat design infographic explaining the experimental method and main results of a study on the protective effects of sulforaphane on acute liver injury. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like mice, and arrows or flow lines indicating the experimental steps. Add a section highlighting the main results, such as reduced liver damage and inflammation. Use a light background with soft colors for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "journal": "GeroScience",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•é©æ‡‰èƒ½åŠ›ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°æ€¥æ€§é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é‹å‹•æ™‚å¯èƒ½ç„¡æ³•ç²å¾—æœ€ä½³çš„å¥åº·ç›Šè™•ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„å¯èƒ½æ€§ï¼Œæˆ–è¨±èƒ½å¤ æ”¹å–„å¹´é•·è€…çš„é‹å‹•åæ‡‰ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡æ€¥æ€§é‹å‹•çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®çµåˆæ˜¯å¦èƒ½å¤ ä¿ƒé€²NRF2çš„æ´»åŒ–ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡ç´°èƒæŠ—æ°§åŒ–å’Œä¿è­·æœ‰é—œçš„ä¿¡è™Ÿå‚³å°æ©Ÿåˆ¶ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼å¹´é•·è€…åœ¨é‹å‹•å¾Œçš„ç”Ÿç†åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•é€éè˜¿è””ç¡«ç´ çš„è¼”åŠ©ä¾†å¢å¼·é€™äº›åæ‡‰ï¼Œå¾è€Œæ”¹å–„ä»–å€‘çš„å¥åº·ç‹€æ…‹ã€‚",
    "para3": "é€™é …ç ”ç©¶çš„å¯¦é©—å°è±¡æ˜¯25ä½å¹´é•·è€…ï¼ŒåŒ…å«12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡ç‚º67æ­²ã€‚åƒèˆ‡è€…é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ã€‚é€™äº›ç´°èƒåœ¨æœ‰å’Œæ²’æœ‰è˜¿è””ç¡«ç´ ï¼ˆ5 ÂµMï¼‰è™•ç†çš„æƒ…æ³ä¸‹é€²è¡ŒåŸ¹é¤Šï¼Œä¸¦è¨­ç½®äº†å››ç¨®è™•ç†æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»åŒ–å’Œç›¸é—œåŸºå› çš„è¡¨é”ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„é¡¯è‘—å¢åŠ äº†NRF2çš„æ´»åŒ–ï¼Œä¸”é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„åæ‡‰å¼·åº¦æ˜é¡¯é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ã€‚è˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—ä¸Šèª¿äº†å››å€‹ç›®æ¨™åŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„è™•ç†åœ¨åŸºå› è¡¨é”ä¸Šæœ‰æ›´å¤§çš„å¢é•·ï¼Œä½†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ ä¹‹é–“çš„å·®ç•°ä¸¦ä¸é¡¯è‘—ï¼Œé€™å¯èƒ½è¡¨æ˜è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šå­˜åœ¨ä¸€å®šçš„ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶çµæœæœªé¡¯ç¤ºæ€§åˆ¥å°åæ‡‰æœ‰é¡¯è‘—å½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•é©æ‡‰èƒ½åŠ›ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°æ€¥æ€§é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é‹å‹•æ™‚å¯èƒ½ç„¡æ³•ç²å¾—æœ€ä½³çš„å¥åº·ç›Šè™•ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„å¯èƒ½æ€§ï¼Œæˆ–è¨±èƒ½å¤ æ”¹å–„å¹´é•·è€…çš„é‹å‹•åæ‡‰ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡æ€¥æ€§é‹å‹•çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®çµåˆæ˜¯å¦èƒ½å¤ ä¿ƒé€²NRF2çš„æ´»åŒ–ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡ç´°èƒæŠ—æ°§åŒ–å’Œä¿è­·æœ‰é—œçš„ä¿¡è™Ÿå‚³å°æ©Ÿåˆ¶ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼å¹´é•·è€…åœ¨é‹å‹•å¾Œçš„ç”Ÿç†åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•é€éè˜¿è””ç¡«ç´ çš„è¼”åŠ©ä¾†å¢å¼·é€™äº›åæ‡‰ï¼Œå¾è€Œæ”¹å–„ä»–å€‘çš„å¥åº·ç‹€æ…‹ã€‚\n\né€™é …ç ”ç©¶çš„å¯¦é©—å°è±¡æ˜¯25ä½å¹´é•·è€…ï¼ŒåŒ…å«12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡ç‚º67æ­²ã€‚åƒèˆ‡è€…é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ã€‚é€™äº›ç´°èƒåœ¨æœ‰å’Œæ²’æœ‰è˜¿è””ç¡«ç´ ï¼ˆ5 ÂµMï¼‰è™•ç†çš„æƒ…æ³ä¸‹é€²è¡ŒåŸ¹é¤Šï¼Œä¸¦è¨­ç½®äº†å››ç¨®è™•ç†æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ ã€é‹å‹•å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»åŒ–å’Œç›¸é—œåŸºå› çš„è¡¨é”ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„é¡¯è‘—å¢åŠ äº†NRF2çš„æ´»åŒ–ï¼Œä¸”é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„åæ‡‰å¼·åº¦æ˜é¡¯é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ã€‚è˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—ä¸Šèª¿äº†å››å€‹ç›®æ¨™åŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„è™•ç†åœ¨åŸºå› è¡¨é”ä¸Šæœ‰æ›´å¤§çš„å¢é•·ï¼Œä½†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ ä¹‹é–“çš„å·®ç•°ä¸¦ä¸é¡¯è‘—ï¼Œé€™å¯èƒ½è¡¨æ˜è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šå­˜åœ¨ä¸€å®šçš„ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶çµæœæœªé¡¯ç¤ºæ€§åˆ¥å°åæ‡‰æœ‰é¡¯è‘—å½±éŸ¿ã€‚",
    "fb_post": "æ ¹æ“šã€ŠGeroScienceã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿå¹´ç´€å¤§äº†ï¼Œé‹å‹•çš„æ•ˆæœå¯èƒ½ä¸å¦‚ä»¥å‰ï¼é€™å°±æ˜¯ç‚ºä»€éº¼æˆ‘å€‘è¦æ¢è¨ä¸€äº›æ–°æ–¹æ³•ï¼Œå¹«åŠ©å¹´é•·è€…æ›´å¥½åœ°ç²å¾—é‹å‹•çš„å¥½è™•ã€‚æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€é—œæ³¨è˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†ï¼Œçœ‹çœ‹å®ƒèƒ½å¦å’Œé‹å‹•çµåˆï¼Œä¾†æå‡å¹´é•·è€…çš„å¥åº·ã€‚\n\nç ”ç©¶è€…é‚€è«‹äº†25ä½å¹´é•·è€…ï¼Œè®“ä»–å€‘é€²è¡Œ30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œç„¶å¾ŒæŠ½å–ä»–å€‘çš„è¡€æ¶²ï¼Œçœ‹çœ‹åœ¨æœ‰æ²’æœ‰æ·»åŠ è˜¿è””ç¡«ç´ çš„æƒ…æ³ä¸‹ï¼Œä»–å€‘çš„èº«é«”åæ‡‰æœ‰ä»€éº¼ä¸åŒã€‚çµæœé¡¯ç¤ºï¼Œç„¡è«–æ˜¯å–®ç¨é‹å‹•é‚„æ˜¯åŠ ä¸Šè˜¿è””ç¡«ç´ ï¼Œå¹´é•·è€…çš„ç´°èƒæŠ—æ°§åŒ–èƒ½åŠ›éƒ½æœ‰æ˜é¡¯æå‡ï¼Œè€Œé‹å‹•åŠ ä¸Šè˜¿è””ç¡«ç´ çš„æ•ˆæœæ›´æ˜¯æœ€ä½³ï¼\n\né€™é …ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé‹å‹•çš„çµåˆèƒ½æå‡å¹´é•·è€…çš„å¥åº·åæ‡‰ã€‚\n2. é‹å‹•ä¸åƒ…èƒ½å¢å¼·èº«é«”ï¼Œæ­é…è˜¿è””ç¡«ç´ æ•ˆæœæ›´ä½³ã€‚\n3. æ€§åˆ¥å°é€™äº›åæ‡‰æ²’æœ‰é¡¯è‘—å½±éŸ¿ã€‚\n\né›–ç„¶é€™äº›çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†æˆ‘å€‘é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå“¦ï¼",
    "image_prompt": "Create an infographic illustrating a research study on the effects of sulforaphane and exercise on elderly individuals. Include simplified icons of broccoli or sulforaphane, representations of human figures or cells as experimental subjects, and arrows or flow lines showing the experimental process. Highlight a section labeled 'Main Results' showing protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  },
  {
    "id": "40763479",
    "title_en": "Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy.",
    "pub_date": "2025 Oct",
    "journal": "International immunopharmacology",
    "abstract_en": "Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚æ–¹é¢ã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸æœƒå°è‡´ç–¼ç—›å’ŒåŠŸèƒ½å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„æ¥µåŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨é é˜²å’Œæ²»ç™‚è‚Œè…±ç—…æ™‚ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ ï¼Œä¾†ä¿ƒé€²èº«é«”çš„è‡ªæˆ‘ä¿®å¾©èƒ½åŠ›ï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ä¸­çš„å·¨å™¬ç´°èƒæ¥µåŒ–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè‚Œè…±ç—…çš„ç™¼ç—…æ©Ÿåˆ¶èˆ‡å·¨å™¬ç´°èƒçš„æ¥µåŒ–æœ‰ä½•é—œè¯ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆèª¿ç¯€é€™ä¸€éç¨‹ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œä¾†æ”¹å–„è‚Œè…±ç—…æ‚£è€…çš„ç—…æƒ…ï¼Œä¸¦æ¸›å°‘ç›¸é—œçš„ç‚ç—‡åæ‡‰ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–ç ”ç©¶äº†è˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢ç´¢è˜¿è””ç¡«ç´ èª¿ç¯€å·¨å™¬ç´°èƒæ¥µåŒ–çš„æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œé€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„æ²»ç™‚æ•ˆæœï¼Œé€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªå°è·¡åˆ†æçµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéJAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çµæ§‹ï¼Œæ¢å¾©äº†è† åŸåŸºè³ªçš„è‡ªç„¶æ’åˆ—ã€‚æ­¤å¤–ï¼Œç•¶åœ°çš„M2å‹å·¨å™¬ç´°èƒæ•¸é‡å¢åŠ ï¼Œè€ŒM1å‹å·¨å™¬ç´°èƒæ•¸é‡æ¸›å°‘ï¼Œé€™æœ‰åŠ©æ–¼ä¿ƒé€²ç‚ç—‡çš„æ¶ˆé€€ã€‚é€™äº›çµæœä¹Ÿåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­å¾—åˆ°äº†é©—è­‰ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚æ–¹é¢ã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸æœƒå°è‡´ç–¼ç—›å’ŒåŠŸèƒ½å—é™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„æ¥µåŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨é é˜²å’Œæ²»ç™‚è‚Œè…±ç—…æ™‚ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ ï¼Œä¾†ä¿ƒé€²èº«é«”çš„è‡ªæˆ‘ä¿®å¾©èƒ½åŠ›ï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œä¸€èˆ¬äººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ä¸­çš„å·¨å™¬ç´°èƒæ¥µåŒ–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè‚Œè…±ç—…çš„ç™¼ç—…æ©Ÿåˆ¶èˆ‡å·¨å™¬ç´°èƒçš„æ¥µåŒ–æœ‰ä½•é—œè¯ï¼Œä»¥åŠè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆèª¿ç¯€é€™ä¸€éç¨‹ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œä¾†æ”¹å–„è‚Œè…±ç—…æ‚£è€…çš„ç—…æƒ…ï¼Œä¸¦æ¸›å°‘ç›¸é—œçš„ç‚ç—‡åæ‡‰ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–ç ”ç©¶äº†è˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒæ¥µåŒ–çš„å½±éŸ¿ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“æ¢ç´¢è˜¿è””ç¡«ç´ èª¿ç¯€å·¨å™¬ç´°èƒæ¥µåŒ–çš„æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œé€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„æ²»ç™‚æ•ˆæœï¼Œé€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶çµæœæ›´å…·èªªæœåŠ›ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªå°è·¡åˆ†æçµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéJAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çµæ§‹ï¼Œæ¢å¾©äº†è† åŸåŸºè³ªçš„è‡ªç„¶æ’åˆ—ã€‚æ­¤å¤–ï¼Œç•¶åœ°çš„M2å‹å·¨å™¬ç´°èƒæ•¸é‡å¢åŠ ï¼Œè€ŒM1å‹å·¨å™¬ç´°èƒæ•¸é‡æ¸›å°‘ï¼Œé€™æœ‰åŠ©æ–¼ä¿ƒé€²ç‚ç—‡çš„æ¶ˆé€€ã€‚é€™äº›çµæœä¹Ÿåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­å¾—åˆ°äº†é©—è­‰ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯å€‹å¥åº·çš„é£Ÿæï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°æ–¼è‚Œè…±ç—…çš„æ²»ç™‚å¯èƒ½æœ‰å¹«åŠ©å“¦ï¼è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œæœƒè®“äººæ„Ÿåˆ°ç–¼ç—›å’Œæ´»å‹•ä¸ä¾¿ã€‚é€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘èº«é«”è£¡çš„å…ç–«ç³»çµ±ï¼Œç‰¹åˆ¥æ˜¯å·¨å™¬ç´°èƒçš„è®ŠåŒ–ã€‚ç ”ç©¶è€…ç”¨å°è€é¼ æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦æ³¨å°„è˜¿è””ç¡«ç´ ï¼Œçµæœç™¼ç¾å®ƒèƒ½æœ‰æ•ˆæ¸›å°‘ç‚ç—‡ï¼Œæ”¹å–„è‚Œè…±çš„å¥åº·ã€‚é€éRNAæ¸¬åºæŠ€è¡“ï¼Œç§‘å­¸å®¶å€‘é‚„ç™¼ç¾è˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€éä¸€æ¢ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœä¸åƒ…åœ¨è€é¼ èº«ä¸Šå¾—åˆ°é©—è­‰ï¼Œç”šè‡³åœ¨äººé¡çš„è‚Œè…±çµ„ç¹”ä¸­ä¹Ÿæœ‰ç›¸ä¼¼çš„è¡¨ç¾ï¼\n\né‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è‚Œè…±ç—…çš„ç‚ç—‡åæ‡‰ã€‚\n2. å®ƒèƒ½èª¿ç¯€å…ç–«ç´°èƒçš„è®ŠåŒ–ï¼Œä¿ƒé€²è‚Œè…±çš„ä¿®å¾©ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that illustrates the experimental methods and main findings of a study on the effects of sulforaphane on tendon disease. The image should have a simple and clear design with a light background. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to indicate the experimental steps. Additionally, include a section labeled 'Main Findings' that highlights protective effects or changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œè…±ç—… Tendinopathy",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40763479/"
  },
  {
    "id": "41060333",
    "title_en": "Sulforaphane from broccoli, an epigenetic modulator in cancer cells.",
    "pub_date": "2025 Oct",
    "journal": "Discover oncology",
    "abstract_en": "The consumption of cruciferous vegetables offers several health benefits due to some of their compounds. Sulforaphane (SFN), a compound found in cabbage and broccoli, has received special attention in recent years due to its anticancer activities. The main objective of this systematic review is to examine the epigenetic and genetic effects of SFN on cancers (in vitro and in vivo) which contribute to its anticancer activities. We only analyzed studies that combined its epigenetic effects and anticancer activities due to the multitude of studies on SFN over the past few years. We found that SFN is able to regulate epigenetic mechanisms and promote the prevention and treatment of several cancers. Definitely, it prevents tumor growth and acts as a histone deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, and a microRNA regulator in several cancers. These epigenetic regulations lead indirectly to a hyperregulation or deregulation of the expression of genes involved in carcinogenesis. SFN hasn't any major epigenetic effect on normal cells. This review revealed that the anticancer activities attributable to SFN are largely related to its ability to modulate cancer cell epigenome. These capabilities to modulate the epigenome make SFN a promising anticancer agent with significant therapeutic potential.",
    "para1": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦ä¾†è‡ªæ–¼å®ƒå€‘æ‰€å«çš„æŸäº›åŒ–åˆç‰©ã€‚è¿‘å¹´ä¾†ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½å°ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æœ‰æ‰€å¹«åŠ©ï¼Œå°¤å…¶æ˜¯å°æ–¼èª¿ç¯€åŸºå› è¡¨é”å’Œå½±éŸ¿ç´°èƒè¡Œç‚ºçš„èƒ½åŠ›ï¼Œé€™äº›éƒ½å¯èƒ½æˆç‚ºæœªä¾†å¥åº·é£²é£Ÿçš„ä¸€éƒ¨åˆ†ã€‚",
    "para2": "é€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†ç™¼æ®æŠ—ç™Œä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨ç´°èƒå…§çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç”±æ–¼éå»å¹¾å¹´æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™é …å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨é‚£äº›åŒæ™‚æ¢è¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰å’ŒæŠ—ç™Œæ´»å‹•çš„ç ”ç©¶ä¸Šã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—ã€‚ç ”ç©¶å°è±¡æ¶µè“‹äº†ä¸åŒçš„ç™Œç—‡é¡å‹ï¼Œä¸¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNA ç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘ä»¥åŠå¾®å°RNAèª¿ç¯€å› å­ï¼Œé€™äº›ä½œç”¨å¯èƒ½å½±éŸ¿ç™Œç´°èƒçš„åŸºå› è¡¨é”å’Œè¡Œç‚ºã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„æŠ—ç™Œæ´»æ€§ä¸»è¦èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›æœ‰é—œã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä¸¦ä¸æ„å‘³è‘—å®ƒä¸€å®šèƒ½æ²»ç™’ç™Œç—‡ï¼Œä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "explanation_zh": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦ä¾†è‡ªæ–¼å®ƒå€‘æ‰€å«çš„æŸäº›åŒ–åˆç‰©ã€‚è¿‘å¹´ä¾†ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½å°ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æœ‰æ‰€å¹«åŠ©ï¼Œå°¤å…¶æ˜¯å°æ–¼èª¿ç¯€åŸºå› è¡¨é”å’Œå½±éŸ¿ç´°èƒè¡Œç‚ºçš„èƒ½åŠ›ï¼Œé€™äº›éƒ½å¯èƒ½æˆç‚ºæœªä¾†å¥åº·é£²é£Ÿçš„ä¸€éƒ¨åˆ†ã€‚\n\né€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†ç™¼æ®æŠ—ç™Œä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨ç´°èƒå…§çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç”±æ–¼éå»å¹¾å¹´æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™é …å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨é‚£äº›åŒæ™‚æ¢è¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰å’ŒæŠ—ç™Œæ´»å‹•çš„ç ”ç©¶ä¸Šã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—ã€‚ç ”ç©¶å°è±¡æ¶µè“‹äº†ä¸åŒçš„ç™Œç—‡é¡å‹ï¼Œä¸¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰æŠ‘åˆ¶åŠ‘ã€DNA ç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰æŠ‘åˆ¶åŠ‘ä»¥åŠå¾®å°RNAèª¿ç¯€å› å­ï¼Œé€™äº›ä½œç”¨å¯èƒ½å½±éŸ¿ç™Œç´°èƒçš„åŸºå› è¡¨é”å’Œè¡Œç‚ºã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„æŠ—ç™Œæ´»æ€§ä¸»è¦èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›æœ‰é—œã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­å…·æœ‰æ½›åŠ›ï¼Œä½†ä¸¦ä¸æ„å‘³è‘—å®ƒä¸€å®šèƒ½æ²»ç™’ç™Œç—‡ï¼Œä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠDiscover oncologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ åƒé’èŠ±æ¤°èœçœŸçš„æœ‰å¥½è™•å—ï¼Ÿæœ€è¿‘çš„ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å°åŒ–åˆç‰©å¯èƒ½æ˜¯æŠ—ç™Œçš„ç§˜å¯†æ­¦å™¨ï¼ğŸŒ±\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„åŸºå› ï¼Œè®“ç´°èƒè®Šå¾—æ›´å¥åº·ã€‚ç ”ç©¶äººå“¡åˆ†æäº†è¨±å¤šå¯¦é©—ï¼Œå¾ç´°èƒåˆ°å‹•ç‰©ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ åœ¨æŠ—ç™Œæ–¹é¢çš„è¡¨ç¾ã€‚çµæœç™¼ç¾ï¼Œå®ƒèƒ½èª¿ç¯€ç´°èƒçš„åŸºå› è¡¨é”ï¼Œé€™å°æ–¼ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚ğŸ’ª\n\né€™è£¡æœ‰å¹¾å€‹é‡è¦çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œå¢åŠ æ”å–å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ã€‚\n2. ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ èƒ½èª¿ç¯€ç™Œç´°èƒçš„åŸºå› è¡¨é”ï¼Œæˆ–è¨±èƒ½å¹«åŠ©é é˜²ç™Œç—‡ã€‚\n3. é›–ç„¶çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„æ•ˆæœï¼\n\nå¿«ä¾†å¤šåƒä¸€äº›é€™äº›å¥åº·çš„è”¬èœå§ï¼ğŸ¥¦",
    "image_prompt": "Create a flat design infographic on a light background that illustrates the experiment and main results of a study on sulforaphane. Include simplified icons of broccoli and sulforaphane, representations of experimental subjects like cells or animals, and arrows or flow lines to show the experimental steps. Add a section labeled 'Main Results' highlighting protective effects or changes observed in cancer cells.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41060333/"
  },
  {
    "id": "40553560",
    "title_en": "Antibacterial effects of sulforaphane - AÂ phytonutrient derived from broccoli asÂ promising candidate in the combat ofÂ bacterial infections.",
    "pub_date": "2025 Oct",
    "journal": "European journal of microbiology & immunology",
    "abstract_en": "Bacterial pathogens, particularly antibiotic-resistant strains may constitute major challenges for the successful treatment of infected patients. Therefore, novel antibiotics or alternative, antibiotics-independent compounds with antimicrobial properties such as phytonutrients are needed. Our systematic literature review summarizes current knowledge on antibacterial effects of sulforaphane (SFN) in vitro and in vivo, including human studies. The isothiocyanate SFN is abundant in plants from the BrassicaceaeÂ family including broccoli. The 28 reports reviewed herein revealed that SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.)Â enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis. In conclusion, given its antibacterial, immune-modulatory, and disease-alleviating effects, SFN constitutesÂ a promising alternative antibiotic-independent candidate for the treatment of bacterial infections, warranting further consideration in clinical trials.",
    "para1": "åœ¨ç•¶ä»Šé†«ç™‚ç’°å¢ƒä¸­ï¼ŒæŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å‡ºç¾ä½¿å¾—æ²»ç™‚æ„ŸæŸ“è®Šå¾—æ›´åŠ å›°é›£ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–å…·æœ‰æŠ—èŒç‰¹æ€§çš„åŒ–åˆç‰©è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ„ŸæŸ“æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç”Ÿç´ ç„¡æ³•æœ‰æ•ˆå°æŠ—çš„æƒ…æ³ä¸‹ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å¸Œæœ›çš„æ›¿ä»£é¸æ“‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ å°æŠ—èŒçš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°æŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸åŒé¡å‹çš„ç´°èŒï¼Œä¸¦è©•ä¼°å…¶åœ¨æŠ—èŒæ²»ç™‚ä¸­çš„å¯èƒ½æ€§ã€‚é€™ä¸åƒ…åŒ…æ‹¬å°ç´°èŒçš„ç›´æ¥å½±éŸ¿ï¼Œé‚„æ¶‰åŠå…¶å°å…ç–«ç³»çµ±çš„èª¿ç¯€ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯ç•¶å‰é†«å­¸ç ”ç©¶ä¸­éå¸¸é—œæ³¨çš„å•é¡Œã€‚",
    "para3": "ç ”ç©¶è€…é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œåˆ†æäº†28ç¯‡æœ‰é—œè˜¿è””ç¡«ç´ çš„ç ”ç©¶å ±å‘Šï¼Œé€™äº›å ±å‘Šæ¶µè“‹äº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—ï¼ŒåŒ…æ‹¬äººé¡ç ”ç©¶ã€‚é€™äº›ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°ä¸åŒç´°èŒçš„æŠ—èŒæ•ˆæœï¼Œä¸¦è©•ä¼°äº†å…¶å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œå¾è€Œæé«˜å°ç´°èŒçš„æŠµæŠ—åŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·æŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ï¼Œæ”¯æŒç´°èŒçš„æ¸…é™¤ï¼Œä¸¦æ¸›å°‘ç‚ç—‡å°ç´°èƒå’Œçµ„ç¹”çš„æå®³ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ›¿ä»£æŠ—ç”Ÿç´ ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "explanation_zh": "åœ¨ç•¶ä»Šé†«ç™‚ç’°å¢ƒä¸­ï¼ŒæŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å‡ºç¾ä½¿å¾—æ²»ç™‚æ„ŸæŸ“è®Šå¾—æ›´åŠ å›°é›£ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–å…·æœ‰æŠ—èŒç‰¹æ€§çš„åŒ–åˆç‰©è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ„ŸæŸ“æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç”Ÿç´ ç„¡æ³•æœ‰æ•ˆå°æŠ—çš„æƒ…æ³ä¸‹ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å¸Œæœ›çš„æ›¿ä»£é¸æ“‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ å°æŠ—èŒçš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°æŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸åŒé¡å‹çš„ç´°èŒï¼Œä¸¦è©•ä¼°å…¶åœ¨æŠ—èŒæ²»ç™‚ä¸­çš„å¯èƒ½æ€§ã€‚é€™ä¸åƒ…åŒ…æ‹¬å°ç´°èŒçš„ç›´æ¥å½±éŸ¿ï¼Œé‚„æ¶‰åŠå…¶å°å…ç–«ç³»çµ±çš„èª¿ç¯€ä½œç”¨ï¼Œé€™äº›éƒ½æ˜¯ç•¶å‰é†«å­¸ç ”ç©¶ä¸­éå¸¸é—œæ³¨çš„å•é¡Œã€‚\n\nç ”ç©¶è€…é€²è¡Œäº†ä¸€é …ç³»çµ±æ€§çš„æ–‡ç»å›é¡§ï¼Œåˆ†æäº†28ç¯‡æœ‰é—œè˜¿è””ç¡«ç´ çš„ç ”ç©¶å ±å‘Šï¼Œé€™äº›å ±å‘Šæ¶µè“‹äº†é«”å¤–å’Œé«”å…§çš„å¯¦é©—ï¼ŒåŒ…æ‹¬äººé¡ç ”ç©¶ã€‚é€™äº›ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°ä¸åŒç´°èŒçš„æŠ—èŒæ•ˆæœï¼Œä¸¦è©•ä¼°äº†å…¶å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œå¾è€Œæé«˜å°ç´°èŒçš„æŠµæŠ—åŠ›ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·æŠ—æ°§åŒ–å’ŒæŠ—ç‚ä½œç”¨ï¼Œæ”¯æŒç´°èŒçš„æ¸…é™¤ï¼Œä¸¦æ¸›å°‘ç‚ç—‡å°ç´°èƒå’Œçµ„ç¹”çš„æå®³ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ›¿ä»£æŠ—ç”Ÿç´ ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of microbiology & immunologyã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿè£¡æœ‰äº›é£Ÿæç«Ÿç„¶èƒ½å°æŠ—ç´°èŒï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆä¾†è‡ªè˜¿è””å’Œé’èŠ±æ¤°èœç­‰é£Ÿç‰©ï¼‰å¯èƒ½æˆç‚ºå°æŠ—æŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„æ–°å¸Œæœ›ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èŒçš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯é‚£äº›å°æŠ—ç”Ÿç´ å·²ç¶“ç„¡æ³•æœ‰æ•ˆçš„ç´°èŒã€‚ç ”ç©¶è€…å€‘åˆ†æäº†28ç¯‡ç›¸é—œçš„ç ”ç©¶ï¼Œæ¢è¨é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿ä¸åŒé¡å‹çš„ç´°èŒï¼Œé‚„æœ‰å®ƒå°æˆ‘å€‘å…ç–«ç³»çµ±çš„æ½›åœ¨å¹«åŠ©ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶å¤šç¨®ç´°èŒçš„ç”Ÿé•·ï¼Œé‚„èƒ½æ¸›å°‘å®ƒå€‘ç”¢ç”Ÿçš„æ¯’æ€§ç‰©è³ªï¼Œåƒæ˜¯ç”Ÿç‰©è†œå’Œæ¯’ç´ ã€‚æ­¤å¤–ï¼Œå®ƒé‚„èƒ½å¢å¼·æˆ‘å€‘çš„æŠ—æ°§åŒ–å’ŒæŠ—ç‚èƒ½åŠ›ï¼Œå¹«åŠ©èº«é«”æ›´æœ‰æ•ˆåœ°æ¸…é™¤ç´°èŒï¼Œæ¸›å°‘ç‚ç—‡å°ç´°èƒçš„å‚·å®³ã€‚\n\nç¸½çµä¾†èªªï¼Œé€™é …ç ”ç©¶çš„é‡é»æ˜¯ï¼š\n- è˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒæœ‰æŠ—èŒæ•ˆæœã€‚\n- å®ƒèƒ½æ¸›å°‘ç´°èŒçš„æ¯’æ€§å› å­ã€‚\n- è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æŠ—ç”Ÿç´ çš„æ›¿ä»£é¸æ“‡ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment and main results of the study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified figures of experimental subjects like humans or cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "èƒƒç‚ Gastritis",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40553560/"
  },
  {
    "id": "40597512",
    "title_en": "In vitro gastrointestinal digestion of broccolis sprout extract: Impact on the bioaccesibility of sulforaphane and total phenolic.",
    "pub_date": "2025 Oct",
    "journal": "Food research international (Ottawa, Ont.)",
    "abstract_en": "Broccoli sprout extract is rich in phenolic compounds and sulforaphane (SFN) and the gastrointestinal digestion process can affect the bioaccessibility of these substances. This study aimed to evaluate the antioxidant capacity and the content of total phenolic compounds (TPC) and SFN in broccoli sprout extract before and during in vitro gastrointestinal digestion (GID). The antioxidant capacity was determined using different assays (FRAP, ABTS and DPPH), and the TPC and sulforaphane content was measured using the Folin-Ciocalteu method and high performance liquid chromatography (HPLC), respectively. The in vitro digestion analyses followed the INFOGEST 2.0 protocol. Additionally, microbiological characterization and chemical composition analysis of broccoli sprouts were conducted. The microbiological analyses indicated that the sprouts were safe for consumption, with high amounts of TPC, antioxidant capacity, and SFN content. The TPC content decreased significantly (pÂ <Â 0.001) after GID, from 1740.0Â Î¼gÂ eq. GAE/g before digestion to 536.5Â Î¼gÂ eq. GAE/g in the gastric phase and 211.0Â Î¼gÂ eq. GAE/g in the enteric phase. The antioxidant capacity also decreased significantly after simulated digestion compared to initial values. A lower (pÂ <Â 0.001) SFN content was identified in the gastric phase (18.6Â mg/g) compared to the intestinal phase (27.8Â mg/g), although both showed lower SFN levels than the undigested sample, which contained 72.2Â mg/g of SFN. In conclusion, simulated digestion significantly reduced the amount of TPC and SFN, likely due to degradation or biotransformation of the compounds under digestion conditions.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•é€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœçš„èƒå–ç‰©å¯Œå«æŠ—æ°§åŒ–ç‰©è³ªï¼Œé€™äº›ç‰©è³ªå°æ–¼ä¿è­·èº«é«”å…å—è‡ªç”±åŸºçš„å‚·å®³æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é›–ç„¶é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–é…šé¡åŒ–åˆç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­å¯èƒ½æœƒæ¸›å°‘ï¼Œä½†é€™äº›æˆåˆ†ä»ç„¶æ˜¯å¥åº·é£²é£Ÿçš„é‡è¦éƒ¨åˆ†ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚æ–¹é¢ã€‚äº†è§£é€™äº›æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°é¸æ“‡é£Ÿç‰©ï¼Œå¾è€Œæå‡å¥åº·ç‹€æ³æˆ–é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèƒå–ç‰©åœ¨æ¨¡æ“¬è…¸èƒƒæ¶ˆåŒ–éç¨‹ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡è®ŠåŒ–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä¸¦å¸Œæœ›äº†è§£é€™äº›è®ŠåŒ–å°æ–¼é’èŠ±æ¤°èœçš„å¥åº·ç›Šè™•æœ‰ä½•å½±éŸ¿ã€‚é€™å°æ–¼æœªä¾†çš„é£²é£Ÿå»ºè­°å’Œé£Ÿå“åŠ å·¥éƒ½æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†æ¨¡æ“¬è…¸èƒƒæ¶ˆåŒ–çš„åˆ†ææ–¹æ³•ï¼Œä¸¦ä¾æ“šINFOGEST 2.0çš„å”è­°é€²è¡Œã€‚ç ”ç©¶å°è±¡æ˜¯é’èŠ±æ¤°èœçš„èƒå–ç‰©ï¼Œä¸¦é€éä¸åŒçš„æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°å…¶æŠ—æ°§åŒ–èƒ½åŠ›å’Œæˆåˆ†å«é‡ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰æ¸¬è©¦ä¾†æ¸¬é‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥åŠä½¿ç”¨Folin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†å¾®ç”Ÿç‰©ç‰¹å¾µåˆ†æå’ŒåŒ–å­¸æˆåˆ†åˆ†æï¼Œä»¥ç¢ºä¿é’èŠ±æ¤°èœçš„å®‰å…¨æ€§ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœèƒå–ç‰©åœ¨æ¨¡æ“¬æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡é¡¯è‘—ä¸‹é™ã€‚ç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼Œé¡¯ç¤ºå‡ºæ¶ˆåŒ–éç¨‹å°å…¶æœ‰æ˜é¡¯å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ çš„å«é‡åœ¨èƒƒç›¸ä¹Ÿé¡¯è‘—ä½æ–¼è…¸ç›¸ï¼Œé›–ç„¶å…©è€…çš„å«é‡éƒ½ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹å¯èƒ½æœƒå°è‡´é€™äº›æœ‰ç›Šæˆåˆ†çš„é™è§£æˆ–è½‰åŒ–ï¼Œé€²è€Œå½±éŸ¿å…¶å¥åº·æ•ˆç›Šã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•é€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœçš„èƒå–ç‰©å¯Œå«æŠ—æ°§åŒ–ç‰©è³ªï¼Œé€™äº›ç‰©è³ªå°æ–¼ä¿è­·èº«é«”å…å—è‡ªç”±åŸºçš„å‚·å®³æœ‰æ½›åœ¨çš„å¥½è™•ã€‚é›–ç„¶é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–é…šé¡åŒ–åˆç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­å¯èƒ½æœƒæ¸›å°‘ï¼Œä½†é€™äº›æˆåˆ†ä»ç„¶æ˜¯å¥åº·é£²é£Ÿçš„é‡è¦éƒ¨åˆ†ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚æ–¹é¢ã€‚äº†è§£é€™äº›æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°é¸æ“‡é£Ÿç‰©ï¼Œå¾è€Œæå‡å¥åº·ç‹€æ³æˆ–é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèƒå–ç‰©åœ¨æ¨¡æ“¬è…¸èƒƒæ¶ˆåŒ–éç¨‹ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡è®ŠåŒ–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä¸¦å¸Œæœ›äº†è§£é€™äº›è®ŠåŒ–å°æ–¼é’èŠ±æ¤°èœçš„å¥åº·ç›Šè™•æœ‰ä½•å½±éŸ¿ã€‚é€™å°æ–¼æœªä¾†çš„é£²é£Ÿå»ºè­°å’Œé£Ÿå“åŠ å·¥éƒ½æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†æ¨¡æ“¬è…¸èƒƒæ¶ˆåŒ–çš„åˆ†ææ–¹æ³•ï¼Œä¸¦ä¾æ“šINFOGEST 2.0çš„å”è­°é€²è¡Œã€‚ç ”ç©¶å°è±¡æ˜¯é’èŠ±æ¤°èœçš„èƒå–ç‰©ï¼Œä¸¦é€éä¸åŒçš„æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°å…¶æŠ—æ°§åŒ–èƒ½åŠ›å’Œæˆåˆ†å«é‡ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰æ¸¬è©¦ä¾†æ¸¬é‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä»¥åŠä½¿ç”¨Folin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œé‚„é€²è¡Œäº†å¾®ç”Ÿç‰©ç‰¹å¾µåˆ†æå’ŒåŒ–å­¸æˆåˆ†åˆ†æï¼Œä»¥ç¢ºä¿é’èŠ±æ¤°èœçš„å®‰å…¨æ€§ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœèƒå–ç‰©åœ¨æ¨¡æ“¬æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡é¡¯è‘—ä¸‹é™ã€‚ç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼Œé¡¯ç¤ºå‡ºæ¶ˆåŒ–éç¨‹å°å…¶æœ‰æ˜é¡¯å½±éŸ¿ã€‚è˜¿è””ç¡«ç´ çš„å«é‡åœ¨èƒƒç›¸ä¹Ÿé¡¯è‘—ä½æ–¼è…¸ç›¸ï¼Œé›–ç„¶å…©è€…çš„å«é‡éƒ½ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹å¯èƒ½æœƒå°è‡´é€™äº›æœ‰ç›Šæˆåˆ†çš„é™è§£æˆ–è½‰åŒ–ï¼Œé€²è€Œå½±éŸ¿å…¶å¥åº·æ•ˆç›Šã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood research international (Ottawa, Ont.)ã€‹æ–¼ 2025 å¹´ 10 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ æœ‰ä»€éº¼ç§˜å¯†å—ï¼Ÿé€™ç¯‡ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œé€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…æ˜¯æœ‰å¯èƒ½çš„ï¼ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é’èŠ±æ¤°èœèƒå–ç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæƒ³äº†è§£é€™äº›æœ‰ç›Šæˆåˆ†åœ¨æˆ‘å€‘æ¶ˆåŒ–æ™‚æœƒç™¼ç”Ÿä»€éº¼è®ŠåŒ–ã€‚\n\nä»–å€‘ä½¿ç”¨äº†æ¨¡æ“¬è…¸èƒƒæ¶ˆåŒ–çš„æ–¹å¼ï¼Œè§€å¯Ÿé’èŠ±æ¤°èœçš„æŠ—æ°§åŒ–èƒ½åŠ›ä»¥åŠè˜¿è””ç¡«ç´ çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœåœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå…¶æœ‰ç›Šæˆåˆ†çš„å«é‡æœƒé¡¯è‘—ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿å®ƒçš„å¥åº·æ•ˆç›Šã€‚\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–ç‰©è³ªå°èº«é«”å¥åº·æœ‰æ½›åœ¨å¥½è™•ã€‚\n2. æ¶ˆåŒ–éç¨‹æœƒå°è‡´é€™äº›æœ‰ç›Šæˆåˆ†çš„é™è§£æˆ–è½‰åŒ–ã€‚\n3. äº†è§£é€™äº›è®ŠåŒ–æœ‰åŠ©æ–¼æˆ‘å€‘é¸æ“‡æ›´å¥åº·çš„é£²é£Ÿï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨é£²é£Ÿå°å¥åº·çš„å½±éŸ¿å§ï¼",
    "image_prompt": "Create an infographic that illustrates the experiment and main findings of a study on broccoli extract and its antioxidant properties. Use flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines to show the experimental steps, and a section highlighting the main results such as the decrease in beneficial compounds during digestion.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40597512/"
  }
]